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Abstract
Maria Paile-Hyvärinen. Depression and Cognition in Type 2 Diabetes. From a 
Life Course Perspective. National Institute for Health and Welfare (THL), Report 
52/2011. 118 pages. Helsinki, Finland 2011. 
ISBN 978-952-245-433-1 (printed), ISBN 978-952-245-434-8 (pdf)
Background
The aetiology of type 2 diabetes is multifactorial; both genetic and environmental 
factors interact in complex manners which are still poorly understood. Furthermore, 
diabetes is linked to several complications which add to both physical and mental 
distress.
Depression is a common co-morbidity of diabetes which can occur both as a 
cause and a consequence of type 2 diabetes. Depression has been shown to correlate 
with glucose regulation and treating depression might prove beneficial for glucose 
regulation as well as for mental well being.
Another complication which might affect diabetes management is cognitive 
decline. Type 2 diabetes is associated with a ~1.5 fold risk of cognitive decline but it 
is not known which subjects with diabetes eventually develop cognitive impairment 
and which ones are likely to be spared. Several other risk factors and complications 
of diabetes might modify the risk for developing cognitive impairment. 
Type 2 diabetes, depression and impaired cognitive performance have all 
been linked to low birth weight. In addition, birth size has been found to modify 
the effect of some previously known risk factors on diabetes. This thesis aimed to 
explore the effects and interactions of birth weight, depression and cognitive ability 
in relation to type 2 diabetes from a life course perspective. 
Subjects and methods
Studies I, II and V were part of the Helsinki Birth Cohort Study. 2003 subjects 
from the original cohort of 8,760 participated in an extensive clinical examination 
at an average age of 61 years. A standard 75 g oral glucose tolerance test (OGTT) 
was performed and depressive symptoms were assessed using the Beck Depression 
Inventory (BDI). BDI scores of 10 or more were regarded as mild to moderate 
depressive symptoms. In addition data was obtained from child welfare clinics 
and national registers. A subset of the cohort (n = 1247) also performed a test 
on cognitive performance (CogState®) at the average age of 64. Furthermore 642 
of the men had completed a test on intellectual ability during their compulsory 
military service at the average age of 20 years.
Studies III and IV were randomised clinical trials where mildly depressed 
diabetic subjects were treated with paroxetine or placebo and the effect on 
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metabolic parameters and quality of life was assessed. The first trial included 14 
women and lasted 10 weeks, while the second trial included 43 subjects, both men 
and women, and lasted 6 months.
Results
Type 2 diabetes was positively associated with the occurrence of depressive 
symptoms. Among diabetic subjects 23.6% had depressive symptoms, compared to 
16.7% of subjects with normal glucose tolerance (OR = 1.77, 95% CI = 1.30 to 2.43, 
p<0.001). Formal mediation analysis revealed that cardiovascular disease (CVD) is 
likely to act as a mediator in the association between type 2 diabetes and depressive 
symptoms (Sobel’s test statistic = 4.00. p<0.001). Furthermore, low birth weight 
was found to modify the association between type 2 diabetes, CVD and depression. 
The association between BDI score and having type 2 diabetes or CVD was twice as 
strong in the subgroup with low birth weight (≤ 2,500g) compared with the group 
with birth weight > 2,500g (p for interaction 0.058). 
In the six months long randomised clinical trial (study IV) the antidepressive 
agent paroxetine had a transient beneficial effect on glycosylated haemoglobin 
A1c (GHbA1c) and quality of life when compared to placebo after three months of 
treatment. 
In study V we found that subjects with known diabetes had a consistently 
poorer level of cognitive performance than subjects with normal glucose tolerance 
in most of the tested cognitive domains. This effect was further amplified among 
those born with a small birth weight (p for interaction 0.002). Intellectual ability in 
early adulthood was not related to any impairment of glucose tolerance at the age 
of 61 years (study I).
Conclusions
Type 2 diabetes is associated with a higher occurrence of depressive symptoms 
compared to subjects with normal glucose tolerance. This association is especially 
strong among subjects with CVD and those born with a low birth weight. Treating 
depressed diabetic subjects with paroxetine has no long term effect on glucose 
regulation.
Physicians should be aware of depression as an important co-morbidity of type 
2 diabetes. Further research is needed regarding the optimal treatment in case of 
co-morbidity. Both depression and the cognitive decline often seen among diabetic 
subjects are increased if the subject is born with a low birth weight. Physicians 
should recognise low birth weight as an additional risk factor and modifier of 
diabetic complications.
Keywords: antidepressant, birth weight, cognitive ability, depression, developmental 
origins, glucose tolerance, intellectual ability, paroxetine, type 2 diabetes.
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Tiivistelmä
Maria Paile-Hyvärinen. Depression and Cognition in Type 2 Diabetes. From a Life 
Course Perspective [Masennus ja kognitiiviset toiminnot tyypin 2 diabeteksessa 
elinkaarinäkökulmasta]. National Institute for Health and Welfare (THL), Report 
52/2011. 118 pages. Helsinki, Finland 2011. 
ISBN 978-952-245-433-1 (printed), ISBN 978-952-245-434-8 (pdf)
Tausta
Tyypin 2 diabeteksen taustatekijät ovat moniulotteisia ja sekä geenit, että ympäris-
tötekijät vaikuttavat yhdessä, toistaiseksi osittain tuntemattomalla tavalla. Diabe-
tes on myös yhteydessä moniin komplikaatioihin, jotka lisäävät niin fyysistä kuin 
henkistäkin kärsimystä.
Masennus on eräs diabeteksen yleinen liitännäissairaus, joka voi ilmaantua 
diabeteksen seurauksena, mutta myös olla diabeteksen riskitekijä. Masennuksen 
ja sokerinsietokyvyn välillä on todettu olevan yhteys ja masennuksen hoitaminen 
saattaa parantaa psyykkisen hyvinvoinnin lisäksi myös sokeritasapainoa.
Kognitiivinen heikentymä on toinen komplikaatio, joka voi vaikeuttaa diabe-
teksen hallintaa. Tyypin 2 diabeetikoilla on todettu olevan noin 1,5-kertainen ris-
ki heikentyneeseen kognitiiviseen suoriutumiseen, mutta on epäselvää mihin dia-
beetikoiden alaryhmään tämä vaikutus eniten kohdistuu. Useat diabeteksen riskit 
ja komplikaatiot saattavat olla mukana muokkaamassa kognitiivisen heikentymän 
todennäköisyyttä.
Tyypin 2 diabeteksen, masennuksen ja kognitiivisen toiminnan on kaikkien 
todettu olevan yhteydessä alhaiseen syntymäpainoon. Lisäksi alhainen syntymä-
paino on osoittautunut muokkaavaksi lisätekijäksi kun tarkastellaan jo ennestään 
tunnettuja diabeteksen riskitekijöitä. Tässä väitöskirjassa tullaan tarkastelemaan 
syntymäpainon, masennuksen, tyypin 2 diabeteksen ja kognitiivisen toiminnan 
yhteisvaikutuksia elämänkaarinäkökulmasta.
Tutkittavat ja menetelmät
Osatyöt I, II ja V olivat osa Helsingin syntymäkohorttitutkimusta. Alun perin 8 760 
henkilöstä koostuvasta kohortista yhteensä 2003 vapaaehtoista osallistui laajaan 
kliiniseen kartoitukseen keskimäärin 61 vuoden iässä. Heille tehtiin mm. vakioitu 
75 g oraalinen sokerirasitustesti ja kartoitettiin masennusoireet Beck Depression 
Inventory (BDI) kyselyn avulla. Lieviksi tai keskivaikeiksi masennusoireiksi 
tulkittiin BDI pisteet ≥ 10. Lisäksi tietoja kerättiin syntymätodistuksista, neuvolan 
ja kouluterveydenhuollon rekistereistä sekä valtakunnallisista terveydenhuollon 
rekistereistä. 1247 henkilöstä koostuva alaryhmä osallistui kognitiivista toimintaa 
mittaavaan testiin (CogState®) keskimäärin 64 vuoden iässä. Lisäksi 642 
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ryhmän miehistä olivat pakollisen asepalveluksensa aikana suorittaneet älyllisen 
suorituskyvyn mittaavan testin keskimäärin 20 vuoden iässä. 
Osatyöt III ja IV olivat kliinisiä lääketutkimuksia, joissa hoidettiin lievästi ma-
sentuneita diabeetikoita paroksetiinilla tai plasebolla ja tutkittiin vaikutusta meta-
bolisiin ja elämänlaatuun liittyviin tekijöihin. Ensimmäisessä kokeessa tutkittiin 
14 naista 10 viikon ajan. Toiseen kokeeseen osallistui 43 henkilöä, joita seurattiin 
6 kuukautta.
Tulokset
Masennusoireita oli 23,6 % diabeetikoista ja 16,7 % henkilöistä, joilla oli normaali 
sokerinsietokyky (OR = 1.77, 95 % CI = 1.30 to 2.43, p < 0.001). Yhteys tyypin 
2 diabeteksen ja masennuksen välillä saattoi välittyä sepelvaltimotaudin 
kautta. Lisäksi havaittiin, että alhainen syntymäpaino muokkaa diabeteksen, 
sepelvaltimotaudin ja masennuksen yhteyttä. Yhteys BDI pisteiden ja diabeteksen 
tai sepelvaltimotaudin välillä oli kaksinkertainen niillä, jotka olivat syntyneet 
pienipainoisina (≤ 2 500 g) verrattuna muihin (interaktion p-arvo = 0.058). 
Kolmen kuukauden paroksetiinihoito alensi glykohemoglobiiniia (GHbA1c) 
ja paransi elämänlaatua paremmin kuin lumelääke. Tämä vaikutus oli kuitenkin 
ohimenevä (osatyö III). 
Viidennessä osatyössä havaittiin, että henkilöillä, joilla oli ennestään tiedossa 
oleva diabetes, oli usealla kognitiivisella osa-alueella heikompi suorituskyky ver-
rattuna niihin, joilla oli normaali sokerinsietokyky. Tämä yhteys oli voimakkaam-
pi pienipainoisina syntyneillä (interaktion p-arvo = 0.002). Nuorella aikuisiällä tes-
tattu älyllinen suoriutuminen ei ollut yhteydessä sokerinsietokykyyn vanhemmalla 
iällä (osatyö I).
Päätelmät
Tyypin 2 diabetesta sairastavilla on enemmän masennusoireita verrattuna niihin, 
joilla on normaali sokerinsietokyky. Tämä yhteys on vielä voimakkaampi henkilöillä, 
joilla on sepelvaltimotauti tai pieni syntymäpaino. Hoidettaessa masentuneita 
diabeetikoita paroksetiinilla ei saada pitkäaikaista hyötyä sokeritasapainoon.
Lääkäreiden kannattaa pitää mielessä masennuksen ja diabeteksen välinen 
yhteisesiintyminen. Näiden sairauksien optimaalisesta yhtäaikaisesta hoidosta tar-
vitaan vielä lisätietoa. Sekä masennus, että diabeetikoilla yleisesti esiintyvä kogni-
tiivinen alenema, ovat yleisempiä pienipainoisina syntyneillä. Pienipainoisuus on 
yksi tyypin 2 diabeteksen komplikaatioita muokkaava riskitekijä. 
Avainsanat: kognitiivinen suoriutuminen, masennus, masennuslääke, paroksetiini, 
sokerinsietokyky, syntymäpaino, tyypin 2 diabetes, varhainen ohjelmoituminen, 
älyllinen suorituskyky 
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1	 Introduction
Type 2 diabetes comprises a vast health care problem which continues to grow in 
all parts of the world (King and Rewers 1993; Harris, Flegal et al. 1998; Connolly, 
Unwin et al. 2000; Wild, Roglic et al. 2004; Peltonen, Korpi-Hyövälti et al. 2006). 
In addition to changes in lifestyle (Ramachandran, Snehalatha et al. 2004), the 
accelerated ageing of the population in many countries also increases the prevalence 
and incidence of type 2 diabetes (Harder, Rodekamp et al. 2007). The aetiology of 
type 2 diabetes is multifactorial; both genetic, environmental and life style factors 
interact. Many risk factors are known, others are certainly yet to be found, and the 
complex relationships and interactions between risk factors need to be explored.
During the past decade low birth weight has been introduced as a new risk 
factor for type 2 diabetes and cardiovascular disease (Forsén, Eriksson et al. 1999; 
Eriksson, Forsen et al. 2001; Harder, Rodekamp et al. 2007; Whincup, Kaye et al. 
2008). Low birth weight has also been linked to depression (Thompson, Syddall 
et al. 2001; Gale and Martyn 2004; Alati, Lawlor et al. 2007), which is a common 
co-morbidity of type 2 diabetes.  In addition, birth size has been found to modify 
the effect of some previously known risk factors on diabetes (Eriksson, Lindi et al. 
2002; Ylihärsilä, Eriksson et al. 2004). It remains to be explored how birth weight 
affects the relationship between type 2 diabetes and depression.
Depression can be both a risk factor and a complication of diabetes and co-
morbid depression complicates the management of glucose homeostasis. It is 
important to recognize this co-morbidity and greater insight is needed in how 
depression and treatment of depression influence the diabetic patient’s treatment 
and overall quality of life.
Another complication which affects diabetes management is cognitive decline. 
Type 2 diabetes is associated with a ~1.5 fold risk of cognitive decline (Cukierman, 
Gerstein et al. 2005) but it is not known which subjects with diabetes eventually 
develop cognitive impairment and which ones are likely to be spared. Other risk 
factors and complications of diabetes might modify the risk for cognitive decline. 
On the other hand baseline intellectual ability might affect both the development 
of diabetes and the risk for future cognitive decline.
This study aimed to explore the effects and interactions of birth weight, 
depression and cognitive ability in relation to type 2 diabetes from a life course 
perspective.
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2	 Review	of	the	litterature
2.1 Definition and diagnosis of type 2 diabetes
Diabetes mellitus is a group of diseases characterized by hyperglycaemia. The 
most common subgroups are type 1 and type 2 diabetes. In type 1 diabetes 
hyperglycaemia is a result of absolute insulin deficiency whereas relative insulin 
deficiency and insulin resistance are the key elements in type 2 diabetes (WHO 
1999; ADA 2007).
Type 2 diabetes (T2D) can be asymptomatic for a long period of time but when 
marked and prolonged hyperglycaemia occurs some of the following symptoms are 
often present: polyuria, polydipsia, involuntary weight loss and sometimes blurred 
vision. 
The standard diagnostic test for type 2 diabetes is the 75g 2-hour oral glucose 
tolerance test (OGTT) where plasma glucose concentrations are measured at 
fasting and two hours after an oral glucose load. Different diagnostic criteria have 
been proposed during the past decades but since 1997 the cut-off points for diabetes 
have been fasting plasma glucose ≥ 7.0 mmol/l or post load plasma glucose ≥ 11.1 
mmol/l according to both the American Diabetes Association (ADA) (ADA 1997) 
and the World Health Organisation (WHO) (WHO 1999). Lesser impairments 
in glucose tolerance are defined as impaired fasting glucose (IFG) and impaired 
glucose tolerance (IGT). The cut-off points for the various disturbances in glucose 
regulation are presented in Table 1.
TABLE 1. WHO 1999 criteria for diagnosing type 2 diabetes based on a 75 g oral glucose 
tolerance test. 
NGT Fasting plasma glucose
Plasma glucose 2 hours after 
glucose load
≤ 6.0 mmol/l and
< 7.8 mmol/l
IFG Fasting plasma glucose
Plasma glucose 2 hours after 
glucose load
6.1 - < 7.0 mmol/l and
< 7.8 mmol/l
IGT Fasting plasma glucose
Plasma glucose 2 hours after 
glucose load
< 7.0 mmol/l and
7.8 - < 11.1 mmol/l
DM Fasting plasma glucose
Plasma glucose 2 hours after 
glucose load
≥ 7.0 mmol/l or
≥ 11.1 mmol/l
NGT = normal glucose tolerance, IFG = impaired fasting glucose, IGT = impaired glucose 
tolerance, DM = diabetes mellitus.
2   Review of the litterature
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2.2 Prevalence of type 2 diabetes 
The registry on medication reimbursement, which is maintained by the Social 
Insurance Institution of Finland provides a means for estimating the prevalence of 
drug treated diabetes in Finland. During the year 2006 there were 169 332 people in 
Finland who were using oral antidiabetic medication either alone or in combination 
with insulin (Reunanen, Virta et al. 2008). This number corresponds to the majority 
of drug treated Type 2 diabetics, although those on insulin treatment only will not 
be included in this group. There are is probably a large proportion of diagnosed 
diabetic patients that are treated with diet only and are thus not recognised by drug 
registers, although according to the more recent treatment guides drug treatment 
should be initiated immediately when the diagnosis is made (Laakso, Reunanen et 
al. 1991; Groop, Virkamäki et al. 2007). Moreover several population based studies 
have shown that around half of those who would fulfil the diagnostic criteria for 
diabetes are yet undiagnosed and thus untreated (King and Rewers 1993; Peltonen, 
Korpi-Hyövälti et al. 2006). 
The prevalence of type 2 diabetes in Finland has been estimated in population-
based studies using oral glucose tolerance tests. In the years 2004–2005 the FIN-
D2D study estimated that the prevalence of type 2 diabetes among 45–74-year-
olds was 16% in men and 11% in women (Peltonen, Korpi-Hyövälti et al. 2006). 
The prevalence has increased markedly since 1992 when another population-based 
study found it to be 10% in men and 7% in women aged 45-64 years (Ylihärsilä, 
Lindström et al. 2005). Based upon these numbers one could estimate that there are 
~ 500 000 Type 2 diabetics in Finland. 
The prevalence of type 2 diabetes is increasing in all age groups but most 
rapidly among the young (Lammi, Taskinen et al. 2007; Lammi, Blomstedt et al. 
2008; Reunanen, Virta et al. 2008). The increasing prevalence of type 2 diabetes 
in Finland is partly explained by the ageing of the population since the incidence 
increases with increasing age (IDF 2007). Other reasons are increasing prevalence 
of obesity and decreased physical activity (Männistö, Lahti-Koski et al. 2004). 
2.3 Pathophysiology of type 2 diabetes
The main feature in type 2 diabetes is an increased insulin demand due to 
insulin resistance in peripheral tissues. Insulin is produced and released from the 
pancreatic β-cells. Its main action is to increase glucose uptake in splanchnic and 
muscle tissue, to inhibit glucose production in the liver and to suppress lipolysis 
and the release of free fatty acids from adipose tissue. Insulin resistance denotes 
the inability of insulin to achieve these effects at normal concentrations. There 
is also a progressive deterioration of β-cell function seen in subjects with type 2 
2   Review of the litterature
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diabetes. When the pancreatic β-cells fail to compensate for the increased insulin 
demand hyperglycaemia follows (Pickup and Williams 2003; Stumvoll, Goldstein 
et al. 2005). 
Type 2 diabetes develops gradually through milder forms of glucose 
intolerance. Impaired fasting glucose (IFG) is a condition where a mild 
hyperglycaemia is present during fasting, whereas in impaired glucose tolerance 
(IGT) hyperglycaemia occurs especially in the postprandial state. Both are risk 
factors for developing type 2 diabetes and are associated with an elevated risk for 
micro- and macrovascular complications (ADA 2007). 
2.4 Risk factors for type 2 diabetes
A large number of risk factors have been associated with type 2 diabetes (Table 
2) including both modifiable and non-modifiable ones. Genetic factors (Altshuler, 
Hirschhorn et al. 2000; Grant, Thorleifsson et al. 2006; Owen and McCarthy 2007; 
Lyssenko, Jonsson et al. 2008), increasing age, male sex (Wild, Roglic et al. 2004), 
a small birth size (Forsén, Eriksson et al. 2000; Whincup, Kaye et al. 2008) and 
low socio-economic status (Connolly, Unwin et al. 2000; Tang, Chen et al. 2003; 
Ramachandran, Snehalatha et al. 2004) can be considered as non-modifiable. The 
potentially modifiable risk factors include obesity and excess visceral fat (Lean, 
Han et al. 1999; Han, Williams et al. 2002), dietary factors (van Dam, Willett et 
al. 2002; Montonen, Knekt et al. 2003), exercise habits (Jeon, Lokken et al. 2007) 
and smoking (Patja, Jousilahti et al. 2005). The risk factors are however very much 
intertwined, often occurring simultaneously and interacting with each other. The 
role of birth size will be discussed in greater detail below.
TABLE 2. Risk factors associated with type 2 diabetes.
Genetic predisposition
Male sex
Increasing age
Low socio-economic status
Hypertension (Gress, Nieto et al. 2000)
Dyslipidemia (Ley, Harris et al. 2009)
Obesity and overweight
Central obesity
High intake of saturated fat 
Low intake of dietary fibre 
Lack of exercise 
Depression 
Cigarette smoking 
Decreased sleep duration (Yaggi, Araujo et 
al. 2006)
Birth size
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2.4.1 Prenatal factors
During the past decades the research on risk factors for several adult diseases has 
evolved from comprising interactions between genes and life style to involving 
foetal and childhood programming effects. The concept of early life origins of 
adult disease was first established in the late 1970’s by Forsdahl (Forsdahl 1977). He 
noticed that there were considerable variations in mortality from coronary heart 
disease between different regions in Norway in a cohort of people born in 1896–
1925. Since the differences could not be explained by socio-economic status in 
adulthood, Forsdahl sought for differences in standard of living in early life using 
infant mortality as an index marker. He found that infant mortality in 1896–1925 
was an independent risk factor for adult cardiovascular mortality in Norway in 
1964–1967. 
The theory of early life origins of adult disease was further developed by Barker 
who expanded the concept and brought to attention the association between low 
birth weight and adult disease. Using a cohort of people born in Hertfordshire 
during 1911–1930 he showed that men who had the lowest weights at birth had 
the highest death rates from ischemic heart disease (Barker, Osmond et al. 1989). 
Later on Barker and his colleagues found associations between low birth weight 
or small size in infancy and several other adult diseases including type 2 diabetes, 
hypertension and the metabolic syndrome (Barker, Osmond et al. 1989; Barker, 
Hales et al. 1993; Barker 1995; Ylihärsilä, Eriksson et al. 2003). 
After Barkers findings many other researchers from around the world have 
continued on the same path and today the field of research is commonly referred 
to as the Developmental Origins of Health and Disease (DOHaD) (Barker 2004; 
Kajantie 2008; Wadhwa, Buss et al. 2009). It has expanded to comprise infant and 
childhood growth as well as foetal development on one end of the life span and 
many different physical, mental and sociological aspects of health and disease on 
the other end. Several intervention studies conducted on animals have confirmed 
the hypothesis of developmental origins of later health outcomes (Ozanne, Wang 
et al. 1996; Fernandez-Twinn, Wayman et al. 2005; McMullen and Mostyn 2009). 
Foetal growth is influenced by many factors: the genome of the foetus, 
maternal nutrition and use of tobacco and alcohol, glucocorticoids, maternal body 
composition, pelvic size and several other pregnancy-specific factors. According to 
the original DOHaD hypothesis suboptimal conditions in utero, often reflected in 
a small size at birth, lead to adaptive changes in the foetus, which may have adverse 
consequences in later life (Barker 1995; Barker 2004). An essential characteristic 
of all living things is the capacity to adapt. The adaptive changes aim to guarantee 
the ability to thrive and reproduce successfully. However, the conditions in utero 
might not be a good forecast of what postnatal and adult life will be and therefore 
the programming might be suboptimal and even predispose to greater health risks. 
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The potential mechanisms behind the programming are referred to as 
epigenetic alterations, i.e. changes in the regulation of gene transcription and 
expression rather than changes in the genome itself. Factors that regulate gene 
expression are e.g. DNA methylation and histone methylation, acetylation and 
phosphorylation (Bird 2002; Villeneuve and Natarajan 2010). Epigenetic changes 
have been shown to be sensitive to intrauterine conditions and interestingly enough 
can even be inherited (Morgan, Sutherland et al. 1999; Waterland and Jirtle 2004). 
Possible pathways of foetal programming are demonstrated in Figure 1.
 
FIGURE 1. Possible pathways of foetal programming of adult disease. Modified from Annals of the New York 
Academy of Sciences (Kajantie 2006). 
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Birth size and type 2 diabetes
As first reported by Hales et al. (Hales, Barker et al. 1991) and recently reviewed by 
Whincup et al there is substantial evidence that links birth size to the risk of type 
2 diabetes (Whincup, Kaye et al. 2008). The risk for type 2 diabetes is increased 
among subjects born small for gestational age as well as among those born large for 
gestational age (Wei, Sung et al. 2003; Harder, Rodekamp et al. 2007). Macrosomia 
is associated with maternal gestational diabetes which is an independent risk factor 
for type 2 diabetes in the offspring (Silverman, Metzger et al. 1995). This work will 
be restricted to discuss the effects of small birth size. 
Low birth weight is associated with both insulin resistance and impaired 
insulin secretion in non-diabetic individuals (Pulizzi, Lyssenko et al. 2009) and 
with a smaller lean body mass and proportionally less muscle tissue at any BMI 
in adulthood (Eriksson, Forsén et al. 2002; Ylihärsilä, Kajantie et al. 2007). Since 
muscle tissue plays an important role in glucose storage and utilisation, reduced 
muscle tissue leads to a higher risk of insulin resistance and could be one possible 
mechanism by which a low birth weight increases the risk for type 2 diabetes. 
Another hypothesized mechanism by which low birth weight may cause type 2 
diabetes is alteration of the HPA-axis, which leads to imbalanced cortisol secretion 
and thus increased insulin resistance (Kajantie 2006; Kajantie 2008). There is some 
evidence that adverse programming in utero can result in a permanent alteration 
of the HPA axis and consequently altered cortisol concentrations throughout life 
(Meaney, Szyf et al. 2007). This may occur as a consequence to intrauterine growth 
retardation as reflected by a small body size at birth (Phillips, Barker et al. 1998; 
Kajantie and Räikkönen 2010).
Birth size as a modifying factor
Small birth size is not only an independent risk factor for several adult diseases but 
has also been shown to modify the effect of previously known risk factors on adult 
disease. Results from the Helsinki Birth Cohort Study have shown that subjects 
born with a low birth weight are more vulnerable to the adverse effects of a low 
socio-economic status with respect to coronary heart disease (Barker, Forsen et 
al. 2001; Eriksson, Yliharsila et al. 2004). In addition, low birth weight has been 
shown to modify the effect of exercise and genetic susceptibility on the risk of 
type 2 diabetes (Eriksson, Lindi et al. 2002; Eriksson, Ylihärsilä et al. 2004; Pulizzi, 
Lyssenko et al. 2009). It remains to be seen whether birth weight has a modifying 
effect on the development of diabetic complications as well.
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2.4.2 Intellectual ability as a predictor of adult disease
During the past decade low intellectual ability has been shown to be a risk factor for 
mortality in several epidemiological cohorts (Hart, Taylor et al. 2003; Batty, Shipley 
et al. 2008). Studies attempting to explain this association (Batty, Deary et al. 2007) 
have observed that low intellectual ability is associated with an unhealthier life 
style (e.g. higher rate of smoking and heavier alcohol consumption), more obesity 
and an increased risk for coronary heart disease which are all known to increase 
overall mortality. The role of socio-economic factors has been explored by Hart et 
al. who claim that IQ is an independent and stronger predictor of mortality than 
overall socio-economic status (SES) (Hart, Taylor et al. 2003). Batty et al. again 
found that education, occupational prestige and income taken together mediated 
the association between IQ and mortality (Batty, Shipley et al. 2008). 
Low SES, smoking, obesity and CHD are all associated with type 2 diabetes 
as well and therefore a direct or indirect association between intellectual ability 
and type 2 diabetes might be expected. There are only a few studies in which this 
association has been examined. Batty et al. have shown that individuals with lower 
IQs are at increased risk for developing the metabolic syndrome. However, the 
negative association which they found between blood glucose and IQ was non-
significant after adjusting for education. 
There are only three published studies where the relationship between early 
life IQ and type 2 diabetes has been explored (Batty, Deary et al. 2007; Batty, Deary 
et al. 2007; Olsson, Hulting et al. 2008). Batty et. al found no association between 
the two in either of their studies while Olsson found a 40% increase in diabetes 
risk for every one standard deviation (SD) decrease in general ability test score 
(Olsson, Hulting et al. 2008). All of these studies have relied on questionnaires 
for the diagnosis of diabetes. However, it has been shown that only around 50% 
of subjects with diabetes are aware of their disease (King and Rewers 1993) and 
therefore the results from these studies could be biased. Moreover, in all of these 
studies the prevalence of type 2 diabetes was assessed at an age less than 55 years. 
Those who develop the disease and have it diagnosed at an early age represent 
an extreme of the type 2 diabetes spectrum and may have different disease and 
risk factors profiles. Therefore there is a need for studies using OGTT to identify 
diabetic subjects and for studies performed in older populations in whom the 
disease is more prevalent. 
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2.5 Complications and co-morbidities of 
 type 2 diabetes
Diabetes is associated with several complications which are related to the duration 
of the disease and to metabolic control. Sustained hyperglycaemia, increased 
concentrations of free fatty acids and inflammatory markers seen in type 2 diabetes 
are risk factors for developing micro- and macroangiopathy, including neuropathy, 
retinopathy, nephropathy, and cardiovascular disease (ADA 2007). There is also 
an increased mortality associated with type 2 diabetes, which is mainly due to 
macrovascular complications (Hu, Stampfer et al. 2001; Eliasson, Talback et 
al. 2008). In addition diabetes has a negative effect on quality of life and mental 
well being (Anderson, Freedland et al. 2001; Grandy S, Chapman RH et al. 2008) 
and on cognitive performance in the elderly (Strachan, Deary et al. 1997). These 
complications can be direct consequences of the metabolic impairments seen in 
type 2 diabetes or they can share a common origin with type 2 diabetes and develop 
side by side. In some cases, e.g. in the case of depression, the same phenomenon 
can be a risk factor predisposing to type 2 diabetes as well as a consequence of type 
2 diabetes (Mezuk, Eaton et al. 2008). Depression and cognitive impairment will be 
discussed in greater detail below.
 
2.5.1 Depression
Prevalence 
Depression is an expanding public health problem with major consequences for 
the individual as well as the society as a whole (Mathers and Loncar 2006). It is one 
of the most common reasons for work disability in Finland (KELA 2008). In the 
Finnish Health 2000 study the 12-month prevalence of major depression according 
to DSM-IV criteria was 4,9% among adults over 30 years of age (Pirkola, Isometsä 
et al. 2005). This is consistent with the world wide prevalence of 4–11 % reported 
by WHO (WHO 2000). In Europe the lifetime prevalence for major depression has 
been estimated to be as high as 12.8% to 30%, (Paykel, Brugha et al. 2005). 
Aetiology and diagnosis
The aetiology of depression is multifactorial and the manifestation of clinical 
depression is always a consequence of several factors interacting. Stressful life 
events have long been known to play a role in the development of depression 
(Agid, Kohn et al. 2000). Also genetic predisposition has repeatedly been described 
(Levinson 2006). Genetic susceptibility has mainly been linked to polymorphisms 
and epigenetic modifications in genes involved in serotonin and glucocorticoid 
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metabolism (Caspi, Sugden et al. 2003; Levinson 2006; McGowan, Sasaki et al. 
2009).
The main symptoms of depression are depressed mood, loss of interest and 
pleasure, low self-esteem, fatigue and loss of energy. Alterations in cognitive 
functions, sleep and appetite are also common. Depression and depressive 
symptoms can be assessed in different ways according to the purpose of assessment. 
For clinical purposes there is a diagnostic convention based on ICD-10 (WHO 
1992) and DSM-IV (APA 2000) criteria. The severity of depression can be assessed 
according to certain threshold values based on the number of symptoms. However, 
the threshold values are arbitrary (Kendler and Gardner 1998) and for many 
purposes it makes more sense to use continuous scales. Beck’s Depression Inventory 
(BDI) (Beck, Ward et al. 1961) is a widely used scale for assessing depressive 
symptoms. It is a 21-item self-report scale where the patient is asked to rate the 
severity of symptoms related to mood, pessimism, self-esteem and body image, 
self-destructive thoughts, social functioning and different somatic manifestations. 
The BDI score ranges between 0 and 63 points and different threshold values have 
been used to indicate severity (Roivainen 2008). In this work ≥10 points was used 
as a cut-off for mild or moderate depressive symptoms as suggested by Beck et 
al.(Beck 1988).
 T2D and depression co-morbidity
The co-morbidity of depression and type 2 diabetes has been established and 
reviewed on several occasions (Gavard, Lustman et al. 1993; Talbot and Nouwen 
2000; Eaton 2002). The most recent meta-analysis found that type 2 diabetes is 
associated with a 60% increased risk for having concomitant depression or 
depressive symptoms and with a 17,6% prevalence of clinically relevant depression 
among type 2 diabetes subjects (Ali, Stone et al. 2006). 
It has been speculated that the association between diabetes and depression is 
merely a reflection of the psychological burden of having a chronic disease (Kessing, 
Nilsson et al. 2003; Knol, Heerdink et al. 2007). However, the results of Timonen 
et al.. argue against this simple explanation by showing that insulin resistance was 
associated with higher depressive symptoms among subjects without a previous 
diagnosis of diabetes (Timonen, Laakso et al. 2005). 
Conversely, as reviewed by Knol et al., depression has been shown to increase 
the risk for onset of diabetes (Knol, Twisk et al. 2006). In fact in light of the most 
recent evidence depression seems to be a stronger predictor of diabetes than 
diabetes is of depression. As reviewed by Mezuk et al. depressed subjects without a 
previous diagnosis of diabetes had a 60% increased risk to develop diabetes during 
follow up when compared to non-depressed subjects. Diabetic subjects had only 
a 15% increased risk of developing depression compared to non-diabetic subjects 
(Mezuk, Eaton et al. 2008).
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Moreover it has been suggested that depression may lead to deterioration in 
glycaemic control in diabetes (Lustman and Clouse 2005). An obvious mechanism 
underlying this association is the fact that depressed individuals are less adherent 
to their treatment and less physically active (Ciechanowski, Katon et al. 2000; 
Lin, Katon et al. 2004; Kilbourne, Reynolds et al. 2005; Pirraglia and Gupta 
2007). Another explanation is that there may be a common underlying hormonal 
or metabolic pathway connecting depression and diabetes (Bjorntorp 2001; 
Musselman, Betan et al. 2003; Golden 2007; Champaneri, Wand et al. 2010). 
Treating diabetic subjects with SSRI
If depression deteriorates glycaemic control, whether through behavioural or 
biological mechanisms, this deterioration could possibly be reversed by treatment 
of depression. Indeed, some antidepressant drugs have been shown to improve 
insulin sensitivity and glucose metabolism. For example, the selective serotonin 
reuptake inhibitor (SSRI), fluoxetine lowers blood glucose levels in type 2 diabetics 
(Gray, Fujioka et al. 1992; O’Kane, Wiles et al. 1994). Some SSRI’s have also been 
shown to promote weight loss, which in itself would improve insulin sensitivity. In 
a recent meta-analysis the mean short-term weight loss induced by fluoxetine was 
found to be 0,94 kg. The long-term effect (0,31 kg after > 4 months of treatment) 
was less marked but still significant (Serretti and Mandelli 2010). Interestingly, 
the effect of fluoxetine on insulin sensitivity also occurs independently of weight 
loss (Maheux, Ducros et al. 1997). There are only a few controlled trials where 
the effect of antidepressive treatment on glucose tolerance has been assessed in 
type 2 diabetic patients particularly treated for depression (Lustman, Griffith et al. 
1997; Lustman, Griffith et al. 1998; Lustman, Freedland et al. 2000; Amsterdam, 
Shults et al. 2006; Lustman, Clouse et al. 2006; Lustman, Williams et al. 2007). The 
question whether the improvement in glycaemic control is linked to improvement 
in depressive symptoms or to a physiological effect of the antidepressant drug is 
still unanswered. Further studies are needed to elucidate this issue. 
2.5.2 Cognitive decline
Cognitive ability declines with age and the prevalence of dementia among people 
over 65 years is estimated to be between 5 and 9 % in Finland (Viramo and Sulkava 
2006). 
Cognitive ability can be assessed in different ways depending on the purpose 
of assessment. Some tests are designed to measure global cognitive function while 
others evaluate different cognitive domains more specifically. The different domains 
which are usually assessed include processing speed/psychomotor performance, 
executive function, short-term and long-term memory, learning and attention. One 
widely used cognitive test is the Mini Mental State Examination (Folstein, Folstein 
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et al. 1975). It is a test designed to measure global cognitive function and is best 
suited to screen for dementia. When assessing more subtle changes in cognition, 
e.g. in epidemiological research, it may be useful to use more sensitive tests such 
as the Cogstate® test battery which will be described in detail below (Darby, Maruff 
et al. 2002).
Type 2 diabetes has been linked to an elevated risk for cognitive impairment. 
It was first reported in the early twenties by Miles and Root (Miles and Root 1922) 
and the continuously growing literature on the subject has been reviewed several 
times (Strachan, Deary et al. 1997; Allen, Frier et al. 2004; Cukierman, Gerstein et 
al. 2005; Biessels, Staekenborg et al. 2006; Kodl and Seaquist 2008). Longitudinal 
studies have shown that diabetes is not only associated with lower cognitive 
performance but also with a higher risk for cognitive decline over time and for 
development of dementia. As reviewed by Cukierman et al. people with diabetes 
have a 1.5 fold risk of cognitive decline compared to people without diabetes. It 
is possible that not all cognitive domains are affected equally by diabetes (Awad, 
Gagnon et al. 2004). Therefore it may be beneficial to assess cognitive ability in 
diabetic subjects with a method designed to detect changes in several different 
cognitive domains. 
Most published studies have focused upon the impact of manifest diabetes on 
cognition (Awad, Gagnon et al. 2004), while evidence regarding pre-diabetic stages 
is more scarce. Findings on the effect of impaired glucose tolerance on cognitive 
performance are not consistent and need further scrutiny (Kalmijn, Feskens et 
al. 1995; Vanhanen, Koivisto et al. 1998; Lindeman, Romero et al. 2001; Messier, 
Tsiakas et al. 2003; Kumari and Marmot 2005; Bonito, Fraia et al. 2007). 
The mechanisms leading to cognitive decline in diabetes are diverse and not 
fully understood. Both micro- and macrovascular disease, which are common 
complications of diabetes, may affect the brain (Biessels, van der Heide et al. 2002; 
Mankovsky and Ziegler 2004; Manschot, Biessels et al. 2007). Depression is another 
common co-morbidity of diabetes (Anderson, Freedland et al. 2001) which can 
affect cognition and can be difficult to differentiate from early stages of dementia 
(Swainson, Hodges et al. 2001). However, it is also possible that hyperglycaemia 
and hyperinsulinaemia per se can affect brain tissue and its metabolism. Several 
insulin receptors and insulin sensitive glucose transporters have been found in 
brain tissue. Also patients with Alzheimer’s disease have been shown to have an 
impaired insulin action in the brain and an elevated concentration of insulin in 
their cerebral spinal fluid. Still, research on the role of insulin in the brain is just 
beginning to evolve (Fujisawa, Sasaki et al. 1991; Manschot, Biessels et al. 2007; 
Kodl and Seaquist 2008). 
Thus, it is not known which aspect of the complex cluster of diabetes and its 
co-morbidities mainly accounts for the association between diabetes and cognitive 
impairment. Likewise it is not known which subjects with diabetes eventually 
develop cognitive impairment and which ones are likely to be spared (Biessels, 
2   Review of the litterature
27Research 52/2011
National Institute for Health and Welfare
Depression and Cognition in
Type 2 Diabetes
Staekenborg et al. 2006). Mounting evidence exists linking low birth weight with 
alterations in cognitive abilities at various stages in life (Richards, Hardy et al. 2001; 
Viggedal 2004; Räikkönen, Forsén et al. 2009). It remains to be seen whether birth 
weight can modify the effect of diabetes on the brain. 
2.6 Summary of the review
Type 2 diabetes is a disease that develops gradually during a long period of time 
and there are many factors throughout the life course which may influence the 
development. Only three studies have attempted to answer the question whether 
type 2 diabetes is predicted by intellectual ability in early adulthood. Therefore 
there has been a call for further investigation of this matter.
The co-morbidity between type 2 diabetes and depression has been established 
but there are still no guidelines for their simultaneous treatment. Some SSRI:s have 
been proven beneficial in the management of both depression and hyperglycaemia 
but the knowledge about other SSRI:s has been scarce.
Type 2 diabetes is also associated with an increased risk of developing cognitive 
impairment. However, the literature on the association between IGT and cognitive 
impairment is less abundant. Moreover the different modifiers and risk factors 
need to be further explored.
A low birth weight has been linked to type 2 diabetes both as an independent 
risk factor and as a modifier of other risk factors. It is also a risk factor for both 
depression and cognitive impairment. The role of birth weight as a modifier of the 
co-morbidity between type 2 diabetes, depression and cognitive impairment has 
not yet been explored.
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3	 Aims	of	the	study
1. To explore intellectual ability as a potential risk factor for T2D. (Study I)
2. To explore associations between glucose tolerance and depression. (Study II)
3. To test the effect of paroxetine on mood and glucose tolerance in diabetic 
subjects. (Studies III–IV)
4. To explore associations between glucose tolerance and cognitive ability. (Study 
V)
5. To explore whether birth weight acts as a modifying risk factor for T2D and its 
complications. (Studies II, V)
29Research 52/2011
National Institute for Health and Welfare
Depression and Cognition in
Type 2 Diabetes
4	 Subjects	and	methods
4.1 The Helsinki Birth Cohort Study
Studies I, II and V were part of the Helsinki Birth Cohort Study. The original 
epidemiological cohort includes 8760 men and women who were born at the 
Helsinki University Central Hospital in 1934-1944. Subjects were included in the 
cohort if they were resident in Finland in 1971, when each member of the Finnish 
population was given a unique personal identification number. 
In the year 2000, postal questionnaires were sent to all cohort members still 
living in Finland (n = 7,078). Out of 3,944 men and women who answered the 
questionnaire and consented to further contact we randomly selected 2,902 subjects 
to be invited to a clinical examination. Finally, 2003 of these subjects participated 
in an extensive clinical examination during the years 2001–2004.
Data collection
Data on the cohort members was obtained from hospital birth records, child welfare 
clinic records, school health care records as well as national Finnish registers. The 
birth records include information on birth weight, birth length and date of mother’s 
last menstrual period, based on which gestational age was calculated. Socio-
economic status in childhood was established based on father’s highest recorded 
occupation, obtained from birth records, child welfare clinic records and/or school 
health care records. 
Clinical examination
A standard 75 g oral glucose tolerance test (OGTT) was performed. For subjects 
who were on insulin treatment (n = 45) only fasting plasma glucose was obtained. 
Height was measured to the nearest centimetre and weight with 0.1 kg 
precision. Body mass index (BMI; kg/m2) was calculated. We assessed depressive 
symptoms using the Beck Depression Inventory (BDI) (Beck, Ward et al. 1961). 
The subjects also filled out detailed questionnaires on current health status and 
medication. The level of education was also obtained from these questionnaires 
and defined by the following four categories: elementary school, vocational school, 
senior high school, college/university degree.
Testing of intellectual ability
Out of the 2003 subjects who participated in the clinical examination 642 men had 
completed a test on intellectual ability during their compulsory military service 
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at the average age of 20 years (range 17–27). These men comprised the study 
sample in study I. The intellectual ability test was designed by the Finnish Defense 
Forces Education Development Centre for the purpose of leadership training 
selections during the military service. It comprises three subtests measuring 
verbal, visuospatial and arithmetic reasoning. Visuospatial intellectual functioning 
is measured by a test analogous to the Raven’s Progressive Matrices which are 
considered to be largely independent of education or socio-cultural factors (Raven 
2000). Each subtest is composed of 40 multiple-choice questions. The test has been 
described in detail by Tiihonen et al. (Tiihonen, Haukka et al. 2005).
Cognitive testing
For the study on cognitive performance (study V) we invited those subjects from 
the original clinical cohort, who were still living in the greater Helsinki area (n= 
1586). 67 subjects were deceased or lost to follow up, 227 subjects declined to 
participate, 5 subjects were not willing or capable of taking the test due to physical 
disabilities, 8 subjects were not capable of taking the test due to poor vision. The 
1,279 subjects who attended were administered a test of cognitive performance in 
the years 2004–2006.
The test used is a standardised, language independent computerised battery 
of cognitive tests (CogState®, version 3.0.5). This battery has been validated and 
shown to be a sensitive indicator of mild impairments in the following cognitive 
domains: psychomotor speed, attention, working memory and episodic learning 
and memory (Collie, Darby et al. 2001; Darby, Maruff et al. 2002; Collie, Maruff 
et al. 2003). The test consists of five tasks where subjects are asked to pay attention 
to playing cards on a computer screen. Each task consists of 30 to 50 repeated 
stimuli described in detail below. The test battery takes approximately 15 minutes 
to complete and is preceded by a practice round. The five tasks are as follows:
1.  Simple reaction time task (SRT) assessing psychomotor function and speed 
of processing. A single card is presented face-down on the computer screen. 
The subject is asked to press the spacebar as soon as the card turns face-up. 
This is repeated 35 times with random time intervals. This task is administered 
twice, first and last in the test, and the mean reaction time from both tasks is 
calculated. 
2.  Choice reaction time task (ChRT) assessing visual attention and requiring a 
binary decision. Subjects are asked to indicate whether the turning playing 
card on the screen is red by pressing either K (“yes”) or D “(no”). The stimulus 
is repeated 30 times and the mean reaction time is calculated. 
3.  Divided attention task (DA). Five playing cards are presented next to one 
another on the computer screen. Two horizontal lines are shown on the screen, 
one above and one below the cards. The five cards move in a disorganised 
manner up and down towards the lines. The subject is asked to monitor all five 
cards simultaneously and press the spacebar as soon as any one of the cards 
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touches either of the lines. The stimulus is repeated 30 times, and the mean 
reaction time is calculated. 
4.  Working memory task (WM). A new playing card is presented 30 times and 
the subject is asked to indicate whether this card is identical to the preceding 
one. Mean reaction time is calculated and the number of correct responses is 
obtained.
5.  Associate learning task (AL) assessing visual learning and memory. In this 
task five pairs of cards are initially presented face-up at the top of the screen. 
At the bottom of the screen a random card pair turns face-up 50 times and 
each time the subject is asked to indicate whether the random pair matches 
exactly any of the pairs above. Upon initial matching, the corresponding card 
pair turns face-down and subsequent matching has to be judged by memory. 
After every match the corresponding card pair is presented for a short while, 
allowing learning by repetition. Speed and the number of correct matches are 
obtained. 
Reaction times were measured in milliseconds and mean reaction times were 
calculated for each subject for each task. Accuracy of responses was recorded as 
the number of correct answers divided by the number of answers given.
Definition of variables
Type 2 diabetes (T2D) and other stages of glucose tolerance were defined according 
to the World Health Organisation (WHO) criteria (WHO 1999) (Table 1). Subjects 
who were taking medication for diabetes and/or reported that they had been 
previously diagnosed with diabetes were categorised as known diabetics (known 
DM). Subjects who were diagnosed with diabetes for the first time by the OGTT 
performed at the clinic where categorized as new diabetics (new DM). Subjects 
who reported being diagnosed with diabetes at an age of 30 years or less were 
categorised as type 1 diabetics if they were on insulin treatment only (n = 4).
Coronary heart disease (CHD) was defined based upon self-report. Subjects 
were asked whether they had a physician-diagnosed history of angina pectoris (n= 
103) or myocardial infarction (n = 67). If not recognised by the previous question, 
subjects using nitrate medication were also defined as having CHD (n = 41, no 
unrecognised). Subjects were defined as having cardiovascular disease (CVD) if, in 
addition to the previously mentioned criteria for CHD, they had a history of stroke 
(n = 53) or claudication (n = 37).
When appropriate, birth weight was dichotomised and a birth weight of 
≤ 2,500 g was regarded as low. When BDI score was dichotomised the cut point 
was set at 10 points and scores of 0 to 9 points were regarded as normal, whereas 
scores of 10 or more were regarded as mild to moderate depressive symptoms 
(Beck, Ward et al. 1961).
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4.2 Clinical trials
Subjects
For studies III and IV we conducted two clinical trials testing the effect of paroxetine 
on glucose tolerance and mental well being in diabetic subjects. Both clinical trials 
included mildly depressed subjects with type 2 diabetes. For trial 1, which was a 
pilot study, we invited only postmenopausal women over 50 years of age. Trial 2 
included both men and women within an age range of 50 to 70 years. All subjects 
were diagnosed with type 2 diabetes at least a year prior to study entry and received 
standard diabetes treatment by their primary care physicians prior to and during 
the trials. They had been on stable antidiabetic medication for at least three months 
before entering the studies. 
In trial 1 we included subjects with an unsatisfactory glycemic control, 
defined as glycosylated haemoglobin A1c (GHbA1c) ≥ 6.5% or fasting blood 
glucose ≥ 7.0 mmol/l, and with a depressive symptoms score between 2.5 and 12 
on the Montgomery-Åsberg's Depression Rating Scale (MADRS) (Montgomery 
and Asberg 1979). This range indicates mild to moderate depressive symptoms 
but not a severe depression requiring immediate treatment. In trial 2 we aimed 
to investigate subjects with worse glycaemic control and set the inclusion criteria 
at GHbA1c > 7.0%. The definition of mild to moderate depression was based on 
the Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM IV) 
(APA 2000). Subjects with 1–6 depressive symptoms according to DSM-IV were 
included in trial 2. 
Subjects with major diabetes complications (e.g. major cardiovascular disease, 
renal insufficiency, blindness, amputations) were excluded from both trials. 
Furthermore, subjects were excluded if they had glaucoma (Eke and Bates 1997) 
and if they were using warfarin (Duncan, Sayal et al. 1998) because of possible 
adverse effects of paroxetine in these conditions. Patients who used any kind of 
antidepressants were also excluded. 
The subjects who met the inclusion criteria were randomly assigned to take 
either placebo or 20 mg paroxetine once a day. In trial 1 this was done in a single-
blind fashion while trial 2 was double-blind. The randomisations were computerised 
and concealed to both the patients, research personnel, and treating physicians 
until inclusion and informed consent was established. In trial 1 the allocation 
remained concealed to the patient, treating physician and laboratory staff, in trial 
2 the allocation remained concealed to all parties. The research personnel did not 
take part in the clinical treatment of the study subjects.
Measurements
In trial 1 we analysed the patients at baseline and after 10 weeks of treatment. 
Mental well being was evaluated using two clinician-rated evaluation scales, 
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Hamilton’s Anxiety Scale (HAM-A) (Gjerris, Bech et al. 1983) and Montgomery-
Åsberg’s Depression Rating Scale (MADRS) (Montgomery and Asberg 1979), and 
two patient-rated scales, Beck’s Depression Inventory (BDI) (Beck, Ward et al. 
1961) and the RAND-36 Item Health Survey (RAND-36) for assessment of quality 
of life (Hays, Sherbourne et al. 1993). In trial 2 we evaluated mental well being 
using the Hospital Anxiety and Depression Scale (HADS) (Zigmond and Snaith 
1983) and quality of life using the the SF-36-Item Short Form Health Survey (SF-
36) (Ware and Sherbourne 1992; McHorney, Ware et al. 1993). The patients were 
analysed at baseline and at 3 and 6 months.
In both trials fasting blood samples were drawn for the following analyses: 
blood glucose, GHbA1c, serum cholesterol, serum HDL-cholesterol, serum cortisol 
and sex hormone binding globulin (SHBG). LDL cholesterol was calculated using 
the Friedewald formula (Friedewald, Levy et al. 1972). Body mass index (kg/m2) 
was calculated using body weight measured to the nearest 0.5 kg and height to 
the nearest cm. All measurements were made after an overnight fast (at least 8 h 
fasting). 
The primary outcome measures in both trials were improvement of GHbA1c 
and the quality of life score. A mean difference between the treatment groups of 0.8 
%-units in GHbA1c and of 20% in the total score of quality of life was considered to 
be clinically significant. 
4.3 Statistical analysis
Studies I, II and V
The intellectual ability test scores in study I were converted into standard deviation 
scores and treated as continuous variables. In study II BDI score was treated as a 
continuous variable and when dichotomised the cut point was set at ≥ 10 points, 
to reflect at least mild severity of depressive symptoms, as suggested by Beck (Beck 
1988). In study V cognitive ability scores were treated as continuous variables 
except for the working memory accuracy which was dichotomised with a cut point 
at two errors. Four subjects had missing information on education. In these cases 
we substituted the missing values with the median value (vocational school) of the 
whole sample. 
Variables with skewed distribution (BDI score, blood glucose, reaction times 
in cognitive performance test) were log-transformed in order to obtain normality. 
Central values of skewed variables are presented as medians and interquartile 
ranges or as geometrical means and standard deviations. 
Multivariate linear regression analyses were used to determine associations 
with continuous outcome variables. When outcome variables were dichotomous 
logistic regression analyses were used. In study I we assessed the association 
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between intellectual ability score and glucose tolerance and odds for having type 
2 diabetes. In study II we assessed the association between BDI score and glucose 
tolerance. In study V the association between glucose tolerance and cognitive 
ability was explored. All analyses were controlled for age and sex. When appropriate 
we controlled for CVD, BMI, education and birth weight to explore potential 
mediation of the associations. In study V we conducted formal mediation analyses 
using Sobel’s test for mediation (Sobel 1982; Baron and Kenny 1986).
Interaction tests and subgroup analyses were conducted to assess whether the 
measured effects varied by sex, birth size, depression or educational attainment.  
Studies III and IV
In study III (clinical trial 1) we calculated mean changes from baseline in metabolic 
parameters and parameters of mental well being. Differences between the two 
treatment groups were calculated using the non-parametric Mann-Whitney 
U-test. The results were recalculated for this thesis using the parametric students 
t-test. Both tests rendered similar results. Only the parametric test results will be 
presented below. Subjects who dropped out of the trial after more than two weeks 
of participation were included in the analysis by last observation carried forward 
technique. 
In study IV (clinical trial 2) differences between the two treatment groups were 
assessed with analysis of covariance (ANCOVA), where baseline measurements 
were used as covariates. Analyses were also controlled for sex, baseline GHbA1c, 
HADS, SF-36 and BMI. Changes from baseline were calculated with a paired 
samples t-test and tabulated as means and 95% CI:s. Kolmogorov-Smirnov-test 
was used to test for normality of the data. 
4.4 Ethical considerations
Studies I, II and V were approved by the Ethics Committee of epidemiology and 
Public Health of the Hospital District of Helsinki and Uusimaa. In addition study 
I was partly approved by the Headquarters of the Finnish Defense Forces. Studies 
III and IV were approved by the Ethics Committee of Helsinki University Central 
Hospital. Each subject participating in the clinical examination of the cohort 
studies and in the clinical trials signed an informed consent form.
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5	 Results
5.1 Intellectual ability as a potential predictor  
 of type 2 diabetes 
In study I we analysed 642 men from the clinical cohort who had completed a 
test on intellectual ability during their military service. 132 (20.6%) of them had 
type 2 diabetes, 132 (20.6%) had impaired glucose tolerance (IGT), 60 (9.4%) had 
impaired fasting glucose (IFG) and 317 (49.5%) had normal glucose tolerance 
(NGT). Intellectual ability scores and other basic characteristics of the study sample 
are listed according to educational level in Table 3. 
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TABLE 3. Intellectual ability scores and socio-economic status at 20 years and metabolic parameters at 61 years according to adult educational level in 
a sample of 641 men from the Helsinki Birth Cohort. 
Elementary 
school n = 178
Vocational 
school n = 142
Senior high 
school n = 176
College or
university n = 145
mean/n SD/% mean/ n SD/% mean/n SD/% mean/n SD/%
Verbal zscore -0.24 0.89 -0.43 0.87 0.38 0.79 0.89 0.75
Visuospatial zscore -0.26 0.93 -0.25 0.96 0.48 0.83 0.80 0.81
Arithmetic zscore -0.35 0.95 -0.28 0.87 0.47 0.78 0.86 0.63
Highest childhood SES 14 7.9 14 9.9 35 19.9 58 40.0
BMI (kg/m2) 28.1 5.3 27.5 3.9 27.6 3.5 26.7 3.4
T2D 43 24.2 33 23.2 33 18.8 23 15.9
zscore = standard deviation score, BMI = body mass index, SES = socio-economic status in childhood, T2D = type 2 diabetes. 
Reproduced with the kind permission from Springer Science + Business Media: Paile-Hyvärinen M, Kajantie E. et al. (2009). “Intellectual ability in early 
adulthood and type 2 diabetes in later life.” Acta Diabetologica 46(3): 249–252.
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Logistic regression models revealed no associations between any of the 
intellectual ability domains and T2D when NGT was used as reference. Neither did 
any of the intellectual ability scores correlate with fasting glucose or 2-hour glucose 
concentrations (Table 4). Analyses were adjusted for age at conscription and age at 
OGTT. Additional adjustment for education, childhood SES or adult BMI did not 
change the results. 
Early intellectual ability was positively correlated with future educational 
attainment (all p-values < 0.001) but intellectual ability scores explained only 19 
to 25% of the variability in education. Therefore, we also separately analyzed the 
association between educational attainment and glucose tolerance. Educational 
attainment was associated with both fasting and 2h-glucose as well as with type 2 
diabetes. Adjusting for intellectual ability in early adulthood or childhood SES did 
not affect the results. However, these associations were somewhat attenuated when 
controlling for BMI (Table 4). There were no interactions between intellectual 
ability test scores and educational attainment in explaining impairments in glucose 
regulation (p-values > 0.5). 
TABLE 4. Associations of intellectual ability and education with glucose tolerance. Effect 
sizes are given as % difference in plasma glucose or as odds ratios for having type 2 
diabetes (T2D), for one standard deviation (SD) change in intellectual ability score or by 
category of educational attainment. Normal glucose tolerance (NGT) was used as reference.
 Fasting glucose 2h-glucose T2D
% (95% CI) % (95% CI) OR (95% CI)
One SD 
increase in IA-
score
 
 
Visuospatial -1.1
(-4.6 to 2.5)
-3.7
(-11.0 to 4.2)
1.02
(0.82 to 1.26)
Verbal -1.5
(-5.1 to 2.1)
-5.0
(-12.4 to 3.0)
0.90
(0.73 to 1.12)
Arithmetic -1.4
(-5.0 to 2.3)
-6.5
(-13.9 to 1.6)
0.93
(0.74 to 1.16)
Educational 
attainment
 
 
 
Lowest Reference Reference Reference
2 -5.0
(-13.7 to 4.6)
-10.7
(-27.8 to 10.6)
0.74
(0.43 to 1.29)
3 -5.1
(-13.4 to 3.9)
-10.7
(-27.0 to 9.3)
0.69
(0.40 to 1.21)
Highest -14.8
(-22.6 to -6.3)
-26.6
(-40.5 to -9.4)
0.50
(0.28 to 0.91)
Highest 
vs. lowest 
education
 
 
Adjusted for 
total IA-score
-16.6
(-25.2 to -6.9)
-27.2
(-42.8 to -7.4)
0.44
(0.22 to 0.88)
Adjusted for 
childhood SES
-14.6
(-22.7 to -5.6)
-24.3
(-39.3 to -5.7)
0.53
(0.28 to 0.98)
Adjusted for 
BMI 
-11.5
(-19.4 to -3.0)
-20.0
(-34.7 to -2.1)
0.75
(0.39 to 1.45)
IA = intellectual ability, SES = socio-economic status in childhood. 
Reproduced with the kind permission from Springer Science + Business Media: Paile-
Hyvärinen M, Kajantie E. et al. (2009). “Intellectual ability in early adulthood and type 2 
diabetes in later life.” Acta Diabetologica 46(3): 249–252.
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5.2 Depression in association with glucose   
 tolerance
Table 5 shows the characteristics of the study sample in study II. Out of the 2003 
men and women 15.7 % had DM, 10.4 % had CVD, 77.5% had neither CVD nor 
DM, and 3.4 % had both. 
TABLE 5. Basic characteristics of 2003 subjects from the Helsinki Birth Cohort. 
Men Women
N Mean (SD)/ % N Mean (SD)/ %
Age (years) 928 61.5 (2.8) 1,075 61.5 (3.0)
Body mass index (kg/m2) 927 27.5 (4.2) 1,074 27.7 (5.0)
Glucose at 0-min (mmol/l) 928 5.8 (5.4 to 6.3)a 1,075 5.4 (5.0 to 5.8)a
Glucose at 120-min (mmol/l) 904 7.1 (5.8 to 9.2)a 1,049 7.1 (5.8 to 8.5)a
Glucose tolerance 926 1,073
Normal 441 47.5 612 56.9
IFG 101 10.9 38 3.5
IGT 203 21.9 293 27.3
DM 181 19.5 130 12.1
Depression (BDI score) 928 4 (2 to 7)a 1,067 5 (2 to 9)a
< 10 points BDI 804 86.6 808 75.2
≥ 10 points BDI 124 13.4 259 24.1
Birth weight (g) 928 3,476 (501) 1,075 3,353 (465)
≤ 2.5 kg 35 3.8 37 3.4
> 2.5 kg 893 96.2 1,038 96.6
CVD No 798 86.0 997 92.7
Yes 130 14.0 78 7.3
a  Median and 25th and 75th percentiles.
IFG = impaired fasting glucose, IGT = impaired glucose tolerance, DM = diabetes mellitus, BDI 
= Beck Depression Inventory, CVD = cardiovascular disease. 
Reproduced with the kind permission from Taylor & Francis: Paile-Hyvärinen M. et al.(2007). 
“Depression and its association with diabetes, cardiovascular disease, and birth weight.” 
Annals of Medicine 39(8): 634–640.
The associations between glucose concentrations and depressive symptoms 
were assessed with linear regression analysis and adjusted for sex. The BDI score 
was positively associated with both fasting and 2h-glucose values. A 10% increase 
in fasting or 2h-blood glucose was associated with a 3.9% (95% CI = 1.9 to 5.9%, 
p < 0.001) and 2.0% (95% CI = 1.0 to 2.9%, p < 0.001) increase in BDI score 
respectively. These associations were slightly smaller but remained significant after 
controlling for age and BMI. 
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We also compared subjects with low BDI scores (< 10p) to those with high 
scores (≥ 10 p). Subjects with mild or moderate depressive symptoms (≥ 10 p) 
had significantly higher plasma glucose values throughout the OGTT, compared 
to subjects reporting low depressive symptoms (< 10 p) (Figure 2).
FIGURE 2. Plasma glucose concentrations during the oral glucose tolerance test according 
to mental well being among subjects from the Helsinki Birth Cohort. Adjusted for gender, 
age and BMI. BDI = Beck depression inventory score.
Reproduced with the kind permission from Taylor & Francis: Paile-Hyvärinen M et al. (2007). 
“Depression and its association with diabetes, cardiovascular disease, and birth weight.” 
Annals of Medicine 39(8): 634–640.
Next we calculated the odds of having mild to moderate depressive symptoms 
in different categories of glucose tolerance. Among diabetic subjects 23.6% had 
depressive symptoms, compared to 16.7% of subjects with normal glucose tolerance 
(OR = 1.77, 95% CI = 1.30 to 2.43, p < 0.001). While further adjustments for age 
and BMI lowered the odds ratio, it still remained significant (OR = 1.43, p = 0.035) 
(Table 6). After adding CVD to the regression model depressive symptoms were 
no longer significantly more prevalent among diabetic subjects (Table 6). Formal 
mediation analysis revealed that CVD is likely to act as a mediator in the association 
between DM and depressive symptoms (Sobel’s test statistic = 4.00. p < 0.001).
Subjects with CVD had more than a twofold risk of having depressive 
symptoms compared to those without CVD (OR = 2.61, 95% CI = 1.88 to 3.62, 
p < 0.001) Controlling for age and BMI did not significantly change the result 
and adding DM to the model did not further explain the variability in depressive 
symptoms. The results remained unchanged after excluding subjects with a history 
of stroke (n = 53). Differences in depressive symptom scores among subjects with 
DM versus CVD are presented graphically in Figure 3.
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TABLE 6. Odds ratios (OR) for having a Beck Depression Inventory score (BDI) ≥ 10 in different categories of glucose tolerance and CVD among 2003 
subjects from the Helsinki Birth Cohort. Normal glucose tolerance/no CVD was used as a reference category.
Model 1 Model 2 Model 3 Model 4
Glucose tolerance OR
(95% CI)
p OR
(95% CI)
p OR
(95% CI)
p OR
(95% CI)
p
Normal 1.0 1.0 1.0 1.0
IFG/IGT 1.41
(1.10 to 1.83)
0.007 1.38
(1.07 to 1.78)
0.014 1.27
(0.98 to1.64)
0.074 1.23
(0.95 to1.61)
0.111
DM 1.78
(1.30 to 2.44)
< 0.001 1.76
(1.28 to 2.41)
< 0.001 1.43
(1.03 to 2.00)
0.035 1.28
(0.91 to 1.80)
0.159
CVD
No 1.0 1.0 1.0 1.0
Yes 2.62
(1.89 to 3.64)
< 0.001 2.53
(1.82 to 3.51)
< 0.001 2.38
(1.70 to 3.31)
< 0.001 2.30
(1.64 to 3.22)
< 0.001
Model 1 gender adjusted, Model 2 + age, Model 3 + BMI, Model 4 + CVD/DM. IFG = impaired fasting glucose, IGT = impaired glucose tolerance, DM = 
diabetes mellitus, BDI = Beck Depression Inventory, CVD = cardiovascular disease, BMI = body mass index.
Reproduced with the kind permission from Taylor & Francis: Paile-Hyvärinen M et al.(2007). “Depression and its association with diabetes, cardiovascular 
disease, and birth weight.” Annals of Medicine 39(8): 634–640.
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FIGURE 3. Depressive symptoms according to CVD and glucose tolerance among subjects 
from the Helsinki Birth Cohort. BDI = Beck Depression Inventory, NGT = normal glucose 
tolerance, DM = diabetes, CVD = cardiovascular disease.
Reproduced with the kind permission from Taylor & Francis: Paile-Hyvärinen M. et al. (2007). 
“Depression and its association with diabetes, cardiovascular disease, and birth weight.” 
Annals of Medicine 39(8): 634–640.
5.3 Treating diabetic subjects with an    
 antidepressant
We performed two controlled clinical trials with diabetic patients treated with 
paroxetine (studies III and IV). In the first trial 14 women, and in the second trial 
43 men and women entered treatment. Baseline characteristics of the subjects in 
the two trials are shown in Table 7.
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FIGURE 4. Flow chart on allocation and drop outs in two clinical trials where mildly 
depressed diabetic subjects were treated with paroxetine or placebo. T1 = 10 week pilot 
rial, T2 = 6 month double blind trial.
Eligible and consenting
T1 (n = 15)     T2 (n = 49)
Randomised to placebo
T1 (n = 7)     T2 (n = 25)
Randomised to paroxetine
T1 (n = 8)     T2 (n = 24)
Received placebo
T1 (n = 7)     T2 (n = 20)
Received paroxetine
T1 (n = 7)     T2 (n = 23)
Analysed at three months
T2 (n = 15)
Analysed at three months
T2 (n = 23)
Completed the trial
T1 (n = 7)     T2 (n = 14)
Completed the trial
T1 (n = 6)     T2 (n = 23)
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TABLE 7. Baseline characteristics of mildly depressed patients with type 2 diabetes. Subjects 
were treated with pareoxetine or placebo during 10 weeks (trial 1) or 6 moths (trial 2). 
Trial 1 Trial 2
Placebo 
(n = 6)
Paroxetine 
(n = 7)
Placebo 
(n = 20)
Paroxetine 
(n = 23)
Mean SD Mean SD Mean SD Mean SD
Sex (M/F) 0/6 0/7 16/4 17/6
Age (years) 62.3 11.5 61.1 8.6 59.5 6.0 59.2 5.4
Body mass 
index (kg/m2)
30.1 6.3 31.6 3.0 32.0 5.3 31.7 5.5
GHbA1c (%) 6.9 0.4 7.5 0.8 8.7 1.3 8.5 0.9
Fasting serum 
glucose 
(mmol/l)
8.4 1.3 8.9 2.8 10.4 3.4 10.4 3.7
Beck’s 
Depression 
Inventory
13.0 9.2 13.7 7.4
Hospital 
Anxiety and 
Depression 
Scale (total 
score)
15.7 5.5 14.0 5.2
Results from trial 1
After ten weeks of treatment the mean decrease in GHbA1c was 0.44%-units (95% 
CI= -0.78 to -0.10, p= 0.019) in the paroxetine group (Table 8). In the placebo 
group GHbA1c decreased only 0.07%-units (95% CI = -0.41 to 0.28, p = 0.64). 
When comparing the two groups to each other there was a trend towards a more 
beneficial outcome in the paroxetine group, although not statistically significant (p 
= 0.08). Fasting blood/serum glucose improved in both groups but the groups did 
not differ significantly from each other (Table 8). 
Improvement in overall quality of life as measured by RAND-36 did not differ 
between the groups (p = 0.59). According to investigator-rated scales there was 
a decrease of anxiety and depressive symptoms in the paroxetine group, but a 
significant difference between paroxetine- and placebo-treated participants was not 
reached. All trial participants improved according to the patient-rated depression 
scale BDI, however, with no significant difference between the groups (paroxetine: 
-6.6 points, 95% CI = -11.9 to -1.2, placebo: -5.8 points, 95% CI = -12.4 to 0.7, p for 
difference between groups = 0.83) (Table 8). 
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TABLE 8. Means (and 95% CI) of metabolic and mental health parameters for type 2 diabetic subjects 
treated with pareoxetine or placebo during a 10 week trial. 
 
 
Placebo Paroxetine
mean 
change
95% CI
mean 
change
95% CI
p for difference 
between groups
Body weight 
(kg) 
-0.83 -1.87 to 0.20 -0.71 -2.83 to 1.40 0.908
Body mass index 
(kg/m2) 
-0.31 -0.71 to 0.09 -0.26 -1.08 to 0.55 0.908
Fasting serum 
glucose (mmol/l)
-0.78 -1.39 to -0.17 -1.47 -3.80 to 0.86 0.529
HbA1c (%) -0.07 -0.41 to 0.28 -0.44 -0.78 to -0.10 0.080
S-cortisol 
(nmol/l) 
104.83 -53.68 to 263.35 -42.29 -165.97 to 81.40 0.089
Energy 
expenditure 
(kcal/d)
-33.33 -198.82 to 132.15 28.57 -135.17 to 192.32 0.523
Hamilton’s 
Anxiety Scale 
-0.67 -5.53 to 4.20 -5.43 -10.35 to -0.51 0.116
Montgomery-
Åsberg’s Rating 
Scale 
-1.50 -5.67 to 2.67 -4.00 -7.20 to -0.80 0.251
Beck’s 
Depression 
Inventory 
-5.83 -12.38 to 0.72 -6.57 -11.93 to -1.21 0.829
RAND-36 129.37 -16.93 to 275.67 60.51 -189.76 to 310.79 0.586
Results from trial 2
After three months of treatment there was a statistically significant improvement 
in GHbA1c in the paroxetine group (mean change from baseline= 0.69%-units, 
p=0.001) and the difference between groups was significant. (Figure 5). Controlling 
for baseline GHbA1c, HADS, SF-36 or BMI did not influence the result. After six 
months the change from baseline in GHbA1c was no longer significant in either 
group and there was no difference between the groups (Table 9). 
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FIGURE 5. Mean changes in glycosylated haemoglobin A1c (GHbA1c) from baseline in 43 type 
2 diabetic subjects receiving placebo or paroxetine. P-value for difference between groups 
at 3 months = 0.018, at six months = 0,693. P-values were calculated using ANCOVA with 
the baseline value as a covariate. Error bars represent 95% CI:s of means.
TABLE 9. Means (and 95% CI) of metabolic parameters for subjects who completed trial 
2. Mean differences between groups were obtained with analyses of covariance with the 
baseline value as a covariate. Means at three and six months are estimated marginal means. 
GHbA1c= glycosylated haemoglobin A1c
Placebo (n = 14) Paroxetine (n = 23) Placebo–Paroxetine
PMean 
(95% CI)
Mean 
(95% CI)
Mean difference 
(95% CI)
GHbA 1 c (%)
Baseline 9.0 (8.2 to 9.8) 8.5 (8.0 to 8.9) 0.54 (-0.24 to 1.31) 0.169
3 months 8.5 (8.2 to 8.9) 7.9 (7.6 to 8.2) 0.59 (0.11 to 1.07) 0.018
6 months 8.4 (7.9 to 8.9) 8.3 (7.9 to 8.7) 0.13 (-0.52 to 0.78) 0.693
Serum glucose (mmol/l)
Baseline 10.7 (8.6 to 12.8) 10.4 (8.8 to 12.0) 0.27 (-2.27 to 2.81) 0.829
3 months 10.7 (9.8 to 12.5) 9.7 (8.2 to 11.1) 1.05 (-1.26 to 3.35) 0.362
6 months 10.8 (9.1 to 12.5) 10.2 (8.8 to 11.5) 0.59 (-1.56 to 2.74) 0.580
Serum C-peptide (nmol/l)
Baseline 0.6 (0.3 to 0.8) 0.7 (0.5 to 0.9) -0.15 (-0.46 to 0.15) 0.310
3 months 0.8 (0.6 to 0.9) 0.8 (0.7 to 1.0) -0.04 (-0.25 to 0.16) 0.656
6 months 0.7 (0.6 to 0.9) 0.8 (0.7 to 0.9) -0.04 (-0.21 to 0.14) 0.682
Body mass index (kg/m2)
Baseline 31.1 (29.3 to 34.1) 31.7 (29.8 to 33.1) -0.66 (-4.14 to 2.82) 0.704
3 months 31.1 (30.7 to 31.6) 31.0 (30.6 to 31.3) 0.15 (-0.44 to 0.73) 0.614
6 months 31.4 (30.9 to 31.9) 31.2 (30.8 to 31.6) 0.15 (-0.47 to 0.77) 0.629
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Overall quality of life, as measured by SF-36, was significantly improved in the 
paroxetine group (Figure 5). After three months of treatment there was a statistically 
significant difference between the two treatment groups in quality of life (mean 
difference = 11.0 points, p = 0.039) which remained significant after controlling for 
baseline SF-36 score, GHbA1c and BMI (Table 10). At the end of the six month trial 
the improvement in SF-36 score from baseline was still statistically significant in 
the paroxetine group, but there was no longer any statistically significant difference 
between the two treatment groups (Table 10) (Figure 6).
FIGURE 6. Mean changes in SF-36 quality of life score from baseline in type 2 diabetic 
subjects receiving placebo or paroxetine. P-value for difference between groups at 3 months 
= 0.039, at six months = 0,135. P-values were calculated using ANCOVA with the baseline 
value as a covariate. Error bars represent 95% CI:s of means.
Anxiety and depressive symptoms decreased in both groups with a trend 
for a stronger effect in the paroxetine group. However, no statistically significant 
difference between the groups was detected at any time point (Table 10). Neither 
was any difference observed in body weight, BMI, serum glucose, serum c-peptide, 
serum cortisol or serum SHBG. 
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TABLE 10. Means (and 95% CI:s) of quality of life and mental health rating scores for 
subjects who completed the study. Mean differences between groups were obtained with 
analyses of covariance with the baseline value as a covariate. Means at three and six months 
are estimated marginal means. HADS = Hospital Anxiety and Depression Scale.
Placebo (n=14) Paroxetine (n=23) Placebo-Paroxetine
Mean (95% CI) Mean (95% CI) Mean difference 
(95% CI)
p
SF-36
Baseline 51.2 (42.6 to 59.8) 56.2 (48.6 to 63.7) -4.7 (-16.3 to 6.4) 0.381
3 months 59.1 (51.2 to 67.0) 70.1 (63.4 to 76.7) -11.0 (-21.4 to -0.6) 0.039
6 months 56.9 (47.5 to 66.2) 65.8 (58.5 to 73.6) -8.9 (-20.8 to 2.9) 0.135
HADS total score
Baseline 15.8 (12.5 to 19.1) 14.0 (11.7 to 16.2) 1.8 (-1.9 to 5.6) 0.327
3 months 11.2 (9.0 to 13.5) 8.5 (6.6 to 10.4) 2.8 (-0.2 to 5.7) 0.066
6 months 12.1 (8.9 to 15.4) 10.2 (7.6 to 12.7) 1.9 (-2.2 to 6.1) 0.351
HADS depression score
Baseline 8.2 (6.2 to 10.2) 7.3 (5.8 to 8.7) 0.9 (-1.4 to 3.4) 0.416
3 months 5.1 (3.8 to 6.3) 3.8 (2.7 to 4.9) 1.3 (-0.4 to 2.9) 0.129
6 months 6.2 (4.6 to 7.7) 5.5 (4.3 to 6.6) 0.7 (-1.2 to 2.7) 0.448
HADS anxiety score
Baseline 7.6 (5.8 to 9.4) 6.7 (5.6 to 7.8) 0.9 (-1.1 to 2.8) 0.366
3 months 6.2 (4.8 to 7.6) 4.6 (3.5 to 5.8) 1.6 (-0.2 to 3.4) 0.085
6 months 6.0 (4.0 to 8.0) 4.7 (3.2 to 6.2) 1.3 (-1.2 to 3.8) 0.312
In order to elucidate whether the response to paroxetine was stronger among 
patients who fulfilled DSM-IV criteria for mild depression we performed a post 
hoc subgroup analysis of covariance. In the subgroup of subjects with five to six 
DSM-IV depressive symptoms [n(placebo) = 4, n(paroxetine) = 5] a significant 
benefit of paroxetine was seen in serum glucose levels after six months (mean 
difference between groups = 3.88 mmol/l, 95%CI = 0.47 to 7.29, p = 0.032). 
5.4 Cognitive performance in different stages  
 of glucose tolerance
In study V the sample consisted of 1,279 subjects from the original clinical cohort, 
who also completed a test on cognitive performance (CogState®). After exclusion 
of subjects with a history of stroke (n = 29), type 1 diabetes (n = 1) and invalid test 
results (n = 3), the sample consisted of 585 men and 658 women. The subjects who 
attended the cognitive test were similar in age, sex, education and prevalence and 
duration of DM to those who did not attend. 
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Inferior cognitive performance correlated with being female, being older, 
and having a lower educational attainment. Median test performance scores are 
shown in Table 11. In Table 12 we show the characteristics of the study participants 
according to glucose tolerance. Age, sex and education were added into all 
regression models since they were strongly associated with the cognitive test scores. 
TABLE 11. Median reaction times and accuracy of performance in the CogState® test among 
subjects from the Helsinki Birth Cohort.
 N
Median 
(%)
25th 
percentile
75th 
percentile
SRT (milliseconds)  1,241 326 297 375
CRT (milliseconds)  1,229 564 510 628
DA (milliseconds)  1,233 483 423 560
WM (milliseconds)  1,235 855 756 1,009
WMhr (errors)  None 480 38.9
  One 312 25.3
  Two or more 443 35.9
AL (milliseconds)  1,233 1,827 1,549 2,182
ALhr (%)  1,233 74.0 66.0 78.9
SRT = simple reaction time, CRT = choice reaction time, DA=divided attention (reaction time), 
WM=working memory (reaction time), WMhr = working memory hit rate, AL = associate 
learning (reaction time), ALhr = associate learning hit rate (% correct answers of all given).
Reprinted from Diabetes Research and Clinical Practice 83(3): 379–386, Paile-Hyvärinen M 
et al. “Impact of glucose metabolism and birth size on cognitive performance in elderly 
subjects.” Copyright (2009), with permission from Elsevier.
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TABLE 12. Characteristics of subjects from the Helsinki Birth Cohort Study, who took the 
CogState® test. Percents represent within glucose tolerance group values. P-value is given 
for the difference when each group is compared to known DM.
  N % or Mean (SD) p
Male sex
NGT 295 43.1% <0.001
IFG/IGT 188 48.7% 0.006
new DM 50 52.1% 0.087
known DM 52 67.5% referent
Age at testing (years)
NGT 684 63.7 (2.8) 0.409
IFG/IGT 386 64.2 (3.0) 0.014
new DM 96 64.0 (2.8) 0.213
known DM 77 63.3 (2.6) referent
Birth weight (g)
NGT 684 3,433 (463) 0.004
IFG/IGT 386 3,381 (486) 0.069
new DM 96 3,406 (514) 0.080
known DM 77 3,253 (571) referent
Coronary heart disease 
NGT 18 2.6% <0.001
IFG/IGT 24 6.2% <0.001
new DM 11 11.5% 0.002
known DM 18 23.4% referent
 Lowest education
NGT 218 31.9% 0.677
IFG/IGT 129 33.4% 0.875
new DM 34 35.4% 0.997
known DM 28 36.4% referent
Highest education
NGT 152 22.2% 0.114
IFG/IGT 80 20.7% 0.234
new DM 12 12.5% 0.999
known DM 10 13.0% referent
NGT = normal glucose tolerance, IFG/IGT = impaired fasting glucose/impaired glucose 
tolerance, new DM = diabetes diagnosed at our clinic 2001–2004, known DM = diabetes 
diagnosed before clinical study.
Reprinted from Diabetes Research and Clinical Practice 83(3): 379–386, Paile-Hyvärinen M 
et al. “Impact of glucose metabolism and birth size on cognitive performance in elderly 
subjects.” Copyright (2009), with permission from Elsevier.
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Glucose tolerance and cognitive performance
We grouped the subjects according to different stages of impaired glucose regulation 
(IFG/IGT, new DM and known DM) and used subjects who had normal glucose 
tolerance as the referent group. Only subjects with known DM had longer reaction 
times and fewer correct responses than NGT subjects (Table 13). Controlling for 
BMI did not attenuate the results. Subjects with IFG/IGT or new DM did not 
differ from the NGT group in any of the tasks. After pooling new and known DM 
together the DM group did not differ from NGT in any of the cognitive tasks (all 
p-values > 0.05).
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TABLE 13. Effect of glucose tolerance on cognitive performance. Numbers indicate per 
cent differences in reaction times and accuracy of performance (hit rate). For the working 
memory task accuracy of performance is given as odds ratios for having made two or more 
errors compared to none or one. Subjects with normal glucose tolerance were used as a 
reference category. Analyses were adjusted for sex, age and education. 
 % (or OR*) (95% CI)   p 
 SRT 
 
 
IFG/IGT 1.6 -0.7 4.0 0.180
new DM 2.3 -1.7 6.5 0.256
known DM 3.7 -0.8 8.4 0.110
 CRT 
 
 
IFG/IGT 1.4 -0.7 3.5 0.190
new DM 0.1 -3.3 3.7 0.954
known DM 5.3 1.2 9.5 0.011
 DA 
 
 
IFG/IGT 0.8 -1.9 3.5 0.562
new DM -1.6 -6.0 3.0 0.485
known DM 2.1 -3.0 7.4 0.433
 WM 
 
 
IFG/IGT 1.0 -1.6 3.7 0.442
new DM 1.1 -3.3 5.6 0.630
known DM 5.7 0.6 11.1 0.027
 WMHR 
 
 
IFG/IGT *1.0 0.8 1.3 0.957
new DM *1.1 0.7 1.8 0.577
known DM *1.9 1.2 3.1 0.010
 AL 
 
 
IFG/IGT -0.2 -3.2 2.8 0.879
new DM -1.2 -6.2 4.0 0.645
known DM 6.7 0.8 13.0 0.027
 ALHR 
 
 
IFG/IGT 0.3 -1.0 1.7 0.629
new DM 0.0 -2.3 2.3 0.994
known DM -3.1 -5.6 -0.5 0.018
NGT = normal glucose tolerance, IFG/IGT = impaired glucose tolerance, new DM = diabetes 
diagnosed at our clinic 2001–2004, known DM = diabetes diagnosed before clinical study, 
SRT = simple reaction time, CRT = choice reaction time, DA = divided attention (reaction 
time), WM=working memory (reaction time), WMh = working memory hit rate ( two or more 
errors), AL = associate learning (reaction time), ALhr = associate learning hit rate (% correct 
answers of all given).
Reprinted from Diabetes Research and Clinical Practice 83(3): 379–386, Paile-Hyvärinen M 
et al. “Impact of glucose metabolism and birth size on cognitive performance in elderly 
subjects.” Copyright (2009), with permission from Elsevier.
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Differences between subjects with known and newly diagnosed DM
Subjects with known DM were different from those with new DM in several 
aspects. Coronary heart disease, high BMI, high BDI scores and low birth weight 
were more common among those with known DM after controlling for sex, age 
and education. However, their level of education was similar to that of the newly 
diagnosed subjects (Table 12). 
The year of diagnosis was available for 82% (n = 63) of the subjects with 
known diabetes. The mean duration of diagnosed DM was 7.6 years (range 0.01 to 
22.5 years). There was no linear association between known duration of diabetes 
and cognitive performance among these subjects.
Tests of mediation
We used Sobel’s formal test for mediation (Sobel 1982; Baron and Kenny 1986) 
to test wether coronary heart disease (CHD) and depressive symptoms acted as 
mediators of the association between diabetes and poor cognitive performance. 
Presence of CHD was associated with a longer reaction time in the AL task (+9.6%, 
p = 0.002) and weakly associated with a longer reaction time in the CRT task 
(+3.9%, p = 0.058). When presence of CHD was added to the models predicting 
cognitive performance, the effect of known DM on AL reaction time was rendered 
non-significant (Table 13). The association between known DM and AL reaction 
time was found to be mediated by the presence of CHD (Sobel test statistic = 2.54, 
p = 0.011). CHD did not mediate the associations between other cognitive tasks 
and known DM.
The BDI score was positively associated with reaction time in the WM task 
(+1.6% for each point increase in BDI score, p = 0.019). Adding BDI score to the 
models predicting cognitive performance attenuated the association between 
known DM and WM reaction time by 17%. The association between known DM 
and WM reaction time was rendered non-significant (p= 0.067) but using Sobel’s 
formal test for mediation did not reveal a statistically significant mediation by BDI 
(Sobel test statistic = 1.8, p = 0.070). 
5.5 Birth weight as a modifying factor of risks  
 and complications of diabetes
Birth weight and depression
In study II logistic regression analyses revealed that subjects who were born with 
a low birth weight (< 2,500 g, n = 72) had a significantly higher risk of having 
depressive symptoms (OR = 2.64, 95% CI = 1.42 to 4.91, p = 0.002) compared to 
those weighing over 2,500 g. Controlling for age, BMI, CVD, DM and gestational 
age did not influence the result. 
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We pooled subjects with DM or CVD or both into one group representing 
subjects with a chronic disease (n = 451). In a linear regression analysis with the 
BDI score as the dependent variable, the interaction between birth weight and 
having a chronic disease was marginally significant (p = 0.058). Subsequently, 
we analyzed subjects with low (< 2,500 g) and normal birth weight (> 2,500 g) 
separately. The association between BDI score and having a chronic disease was 
significant in both groups but it was twice as strong in the group with low birth 
weight as in the group with birth weight > 2,500 g (Figure 7). Thus low birth weight 
was found to strengthen the previously established association between chronic 
disease and depression.
FIGURE 7. Depressive symptoms according to birth weight and presence of chronic disease 
among subjects from the Helsinki Birth Cohort Study. DM = diabetes, CVD = cardiovascular 
disease, BDI = Beck Depression Inventory. 
Reproduced with the kind permission from Taylor & Francis: Paile-Hyvärinen M. et al. (2007). 
“Depression and its association with diabetes, cardiovascular disease, and birth weight.” 
Annals of Medicine 39(8): 634–640.
Birth weight and cognitive performance
In study V birth weight was negatively associated with reaction time in the DA task 
(-3.8%/kg, 95% CI = -6.5 to -1.1, p = 0.005) and with hit rate in the AL task (-1.5%/
kg, 95% CI = -0.1 to -2.9, p = 0.036) after adjustment for age, sex and gestational 
age. The result was not altered by further adjustment for CHD, DM, depressive 
symptoms and education. We also found a significant interaction between birth 
weight and known DM when predicting the reaction times in the WM (p = 0.002) 
and AL (p = 0.009) tasks and a marginally significant interaction when predicting 
the CRT task (p = 0.052). A low birth weight was associated with longer WM and AL 
reaction times only among subjects with known DM, whereas the reaction times of 
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subjects in other glucose tolerance categories were not influenced by birth weight 
(Figure 8). Adding CHD to the interaction models did not affect this finding.
FIGURE 8. Reaction times in working memory (WM) and associate learning (AL) tasks for 
known diabetic subjects compared to others according to birth weight (bwt). P-values for 
interaction between birth weight and known DM in WM: p = 0.002, in AL: p = 0.009. Known 
DM = diabetes diagnosed before clinical study 2001–2004, other = subjects with normal 
glucose tolerance, impaired glucose tolerance or newly diagnosed diabetes. 
Reprinted from Diabetes Research and Clinical Practice 83(3): 379–386, Paile-Hyvärinen M 
et al. “Impact of glucose metabolism and birth size on cognitive performance in elderly 
subjects.” Copyright (2009), with permission from Elsevier.
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6	 Discussion
6.1 Depression and diabetes
The prevalence of diabetes in our study population was 15.5%, which is consistent 
with previous population based studies (Peltonen, Korpi-Hyövälti et al. 2006; 
Reunanen, Virta et al. 2008). The prevalence of depressive symptoms was 19.1%. 
This is somewhat higher than previously reported (Kessler, McGonagle et al. 1994; 
Kessler, Chiu et al. 2005; Pirkola, Isometsä et al. 2005), which is probably due to the 
older age of our study population and the fact that self report scales give a higher 
estimate of depression than formal diagnostic assessment (Musselman, Betan et 
al. 2003). In accordance with previous findings (Lustman, Anderson et al. 2000; 
Anderson, Freedland et al. 2001) we showed that type 2 diabetes was positively 
associated with the occurrence of depressive symptoms. Among diabetic subjects 
almost one fourth (23.6%) had a BDI score ≥10p. 
The strength of our study is that we did not rely on hospital records or self-
report for diagnosis of diabetes. Type 2 diabetes often goes undiagnosed for many 
years (King and Rewers 1993) and studies which rely on hospital records or self-
report for diagnosis of their subjects are prone to selection-bias. We were also able 
to control the results for birth weight, which is essential since low birth weight 
has been associated with both type 2 diabetes and depression and might thus act a 
confounding factor.
Depression has previously been regarded as a co-morbid condition resulting 
from the daily burden of having diabetes and/or its complications, or from having 
a chronic disease. Some studies even suggest that it is the complications associated 
with diabetes that may induce depressive affect rather than having diabetes per se 
(Pouwer, Beekman et al. 2003; Bruce, Casey et al. 2006). In our study the association 
between diabetes and depressive symptoms was rendered non-significant after 
controlling for CVD, whereas the presence of CVD, regardless of diabetes, more 
than doubled the odds of having depressive symptoms. 
Our findings are consistent with those of Pouwer et al. (Pouwer, Beekman et 
al. 2003) who compared diabetic subjects with co-morbid disease (CVD, asthma 
or emphysema) to subjects with diabetes without co-morbidities and found that 
only the ones who had diabetes in combination with another disease differed from 
healthy controls in terms of depression. These findings may be partly explained 
by the fact that subjects with DM but without CVD often have less symptoms of 
disease than those with both DM and CVD and would thus be less distressed by 
their condition. 
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However, during the past few years evidence has emerged arguing for another 
type of link. Depression has been shown to precede type 2 diabetes and has lately 
rather been regarded as a risk factor for the disease. In addition to behavioural 
pathways associated with depression, including altered dietary and exercise habits, 
there are several physiological mechanisms which may underlie the associations 
between diabetes, CVD and depression. 
Subclinical hypercortisolism and other characteristics of an impaired HPA-
axis are often seen in depressed subjects (Pariante and Lightman 2008; Champaneri, 
Wand et al. 2010). Furthermore there are elevated levels of inflammatory markers 
and cytokines such as C-reactive protein (CRP), interleukin-6 (IL-6) and Tumor 
Necrosis Factor α (TNF-α) (Weinstein, Deuster et al.; Gimeno 2009; Stewart, Rand 
et al. 2009). Proinflammatory cytokines are known to activate the HPA-axis and 
both cortisol and cytokines can have damaging effects on the central nervous system 
thus contributing to the pathogenesis of depression (Miller and O’Callaghan 2005; 
Herbert, Goodyer et al. 2006). 
Likewise a range of inflammatory components seem to play an important role 
in the development of diabetes. Several studies have found associations between 
various inflammatory markers and type 2 diabetes (Schmidt, Duncan et al. 1999; 
Champaneri, Wand et al. 2010). Most recently a longitudinal study by Bertoni et 
al. showed that the inflammatory markers CRP, IL-6 and fibrinogen predicted the 
incidence of type 2 diabetes. Another frequently observed feature of type 2 diabetes 
is hypercortisolism and alterations of the HPA-axis. Perturbation of the HPA-axis 
has been linked to insulin resistance and type 2 diabetes in several studies (Phillips, 
Barker et al. 1998; Björntorp, Holm et al. 1999; Chiodini, Adda et al. 2007). 
Thus, several similar alterations are seen in depression and type 2 diabetes and 
the same factors seem to promote both insulin resistance and depression. Hence, a 
biological basis for the co-morbidity is conceivable.
6.1.1 Treating depression in diabetic subjects
Previous studies have shown that treating depression can improve glucose tolerance 
in addition to improving mood. We observed that the antidepressive agent 
paroxetine had a beneficial effect on GHbA1c and quality of life when compared to 
placebo after three months of treatment. However, when treatment was continued 
the difference between groups was no longer significant. In the preceding pilot 
study we found no statistically significant difference between the treatment groups 
in either glucose tolerance or mental well being.
The pilot study had several weaknesses, i.e. small sample size, (N = 15), lack of 
double-blindness, short duration (10 weeks), and a rather good baseline metabolic 
control (mean GHbA1c 7.5 %). We aimed at overcoming the weaknesses of the pilot 
trial by performing the 6-month double-blind trial with stricter inclusion criteria 
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for glycaemic control (>7 % vs. ≥ 6.5 % in the previous trial). In the 6 month trial 
we saw a minor effect of parxetine on GHbA1c.
Our primary outcomes, which we considered to be clinically significant, 
were a 0.8%-units difference in GHbA1c and a 10 points difference in SF-36 when 
comparing paroxetine to placebo. Our finding of a 0.59%-units difference) but in 
GHbA1c did not reach our primary definition of clinical significance and the effect 
was transient. A similar transient treatment effect was seen in a study by Gray et al 
(Gray, Fujioka et al. 1992) exploring the effect of fluoxetine on GHbA1c. 
One explanation to the limited findings could be related to the low level 
of depression in our sample. Only ten subjects fulfilled the DSM-IV criteria for 
mild depression. A study by Weber-Hamann et al. suggests that the effect of 
antidepressants on glycaemic control is related to the improvement in depressive 
symptoms and showed that only the ones who responded to paroxetine treatment 
showed improved insulin sensitivity (Weber-Hamann, Gilles et al. 2006). We did 
not see a significant improvement in depressive symptoms by the end of six months, 
which could explain the lack of effect on glycaemic control. A statistically, significant 
improvement in SF-36 was reached after three months of treatment. However, by 
the end of the trial, the effect on quality of life was somewhat diminished and the 
difference between groups was no longer significant.
Our post hoc subgroup analysis suggested that a possible long term effect 
on glucose tolerance could be confined to those who fulfil criteria for clinical 
depression. Lack of power restricted our possibility to test whether this effect 
correlated with improvement in depressive symptoms. 
Based on previous studies with fluoxetine we expected to see greater effects 
of paroxetine on metabolic parameters. It is possible that the effect of paroxetine 
differs from that of fluoxetine despite both being selective serotonin re-uptake 
inhibitors (SSRI). SSRI’s are usually associated with weight loss. However, a recent 
meta-analysis found that the marginal weight loss seen in short term treatment of 
depression with paroxetine shifted into weight gain when treatment was continued 
for over four months (Serretti and Mandelli 2010). A study performed in vitro 
indicated that paroxetine could even induce insulin resistance in rat liver cells 
(Levkovitz, Ben-shushan et al. 2007). This could partly explain why we did not see 
the expected beneficial effect on glucose tolerance with paroxetine. 
Our study was the first long-term double-blind placebo-controlled study where 
paroxetine was used to treat type 2 diabetic subjects with mild depressive symptoms 
and effects on mental well being and metabolic control were simultaneously 
assessed. Our findings suggest that diabetic patients with sub-threshold depression 
do not benefit from a long-term treatment with paroxetine.
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6.2 Type 2 diabetes and cognitive ability
The association between type 2 diabetes and cognitive decline has been well 
established (Awad, Gagnon et al. 2004). Less has been published about how 
prediabetic stages affect cognition and about the effects of having previously 
diagnosed diabetes as opposed to newly diagnosed. 
In study V we found no association between newly diagnosed diabetes or 
lesser impairments in glucose regulation and cognitive performance. However, 
subjects with known diabetes had a consistently poorer level of performance than 
subjects with normal glucose tolerance in most of the tested cognitive domains. 
The absence of a correlation between IFG/IGT and cognitive performance 
is consistent with the findings of Lindeman et al. and Kumari et al. (Lindeman, 
Romero et al. 2001; Kumari and Marmot 2005). However there are also studies 
where a negative effect on cognitive performance has already been noted among 
subjects with IGT (Kalmijn, Feskens et al. 1995; Vanhanen, Koivisto et al. 1998; 
Bonito, Fraia et al. 2007). 
Our finding regarding the effect of known DM on cognition might be 
attributed to a longer duration of the disease among those who already have a 
diagnosis. Although part of the subjects with newly diagnosed diabetes might 
have had DM for years without knowing it, we believe that those who have been 
diagnosed with DM have on average developed the disease earlier than those who 
have not been diagnosed. Thus, they have potentially been affected by impaired 
glucose regulation during a longer time period and developed more co-morbidities. 
Another possibility is that those who have a diagnosis have a more complicated and 
symptomatic form of disease to begin with. As shown in table 12 the subjects with 
known DM differed from the ones with newly diagnosed DM in several aspects. 
They had higher BMI, more CHD and were born with a lower birth weight. 
One apparent mechanism by which cognitive impairment can develop in 
diabetic subjects is through the macrovascular and microvascular co-morbidity 
associated with diabetes. In our sample subjects with known DM had more CHD 
than those with newly diagnosed DM. However, CHD only mediated the effect 
of known DM in one task (AL reaction time). Even so, this does not exclude 
the possibility that vascular changes play a role in mediating impairment of 
other cognitive domains as well. In fact, a recent work by Park et al. shows that 
intracranial atherosclerosis can be present among subjects with the metabolic 
syndrome independently of extracranial atherosclerosis (Park, Kwon et al. 2007), 
which indicates that CHD may not always be a very sensitive marker for intracranial 
macrovascular disease. 
Other possible mediators are hyperglycaemia, hyperinsulinaemia, 
dyslipidaemia and microvascular disease. Unfortunately we had no data on 
microvascular disease among the subjects, and their blood samples were not drawn 
at the time of cognitive testing. Thus we could not explore the mediating effects of 
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these factors. However, based on samples of blood glucose taken from a subgroup 
of the study subjects (unpublished data) we speculate that subjects with known DM 
have worse glucose homeostasis than subjects with new DM. This could give rise to 
more microvascular changes in the brain (Mäkimattila S, Malmberg-Cèder K et al. 
2004) and thus explain part of our result. 
6.2.1 Premorbid cognitive ability
The association between type 2 diabetes and low cognitive ability could also be 
influenced by pre-morbid cognitive ability. A low general ability might act as a risk 
factor for developing type 2 diabetes and thus subjects with diabetes would have 
lower cognitive ability already before developing the disease. Most studies on the 
effect of diabetes on cognition are controlled for education. However, our results 
from study I indicate that early intellectual ability test scores explain less than 25% 
of the variability in educational attainment. Thus controlling for education can only 
partly account for pre-morbid cognitive ability. But is pre-morbid cognitive ability 
a crucial confounding factor when assessing the effect of diabetes on cognition?
Since previous findings on the subject have been contradictory we set out 
to explore the effect of early intellectual ability on the risk of developing type 2 
diabetes. We found no association between intellectual ability in early adulthood 
and impairment in glucose regulation at age 61 years. However, type 2 diabetes 
was predicted by low educational attainment. These results suggest that diabetes is 
predicted by aspects of educational attainment above and beyond those reflected 
in measures of intellectual ability. These may include factors related to socio-
economic status, place of residence and lifestyle, which is illustrated by the fact that 
controlling for BMI attenuated the association between education and prevalence 
of diabetes. 
Our results differ from those of Olsson et al. (Olsson, Hulting et al. 2008)# 
but there are several important differences between the studies which may explain 
the different results. The Olsson study did not control for current education or 
socio-economic status, which seem to be of major importance. Furthermore, the 
study samples differed in age at both the initial testing for intellectual ability and at 
assessment of diabetes. In the Olsson study subjects had an average age of 42 and 
diabetes diagnosis was based on interviews. The overall diabetes prevalence was 
low, being only 0.8%. This young population is likely to represent an extreme of 
the type 2 diabetes spectrum and thus the association with intellectual ability may 
be dissimilar in this subgroup. The public health burden of type 2 diabetes is more 
accurately indicated by our study, with a 21% prevalence of diabetes assessed by 
OGTT at 61 years. 
To conclude, better educational attainment seems to protect men from 
developing type 2 diabetes whereas we found no evidence that intellectual ability 
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per se would do so. Longitudinal studies with assessment of cognitive ability at 
a young age and subsequent follow up with a focus on diabetes and cognition 
would shed more light into the association between pre-morbid and post-morbid 
cognitive ability in relation to diabetes.
6.3 Birth weight as a modifying factor
As discussed previously, the temporal and causal pathways linking depression, type 
2 diabetes, and cognitive performance are complex. It seems likely that there are 
yet unresolved factors underlying all of these disorders which make certain people 
more vulnerable to this cluster of diseases. A possible common causal link between 
depression, type 2 diabetes, and cognitive decline is altered function of the HPA axis 
since elevated cortisol levels have been reported in all of these disorders (Nemeroff, 
Widerlov et al. 1984; Freeman, Nixon et al. 1987; Chiodini, Torlontano et al. 2005; 
Weber-Hamann, Gilles et al. 2006) (Rosmond and Bjorntorp 2000; Kajantie 2006). 
Altered HPA function has been associated with a small body size at birth (Phillips, 
Barker et al. 1998). Therefore we set out to explore the impact of birth size on the 
above mentioned disorders and their associations.
6.3.1 Depression
In accordance with previous findings we observed that low birth weight (≤ 2,500 g) 
was associated with depressive symptoms (Thompson, Syddall et al. 2001; Gale 
and Martyn 2004; Alati, Lawlor et al. 2007; Räikkönen, Pesonen et al. 2007). 
This association remained equally strong even after adjusting for the occurrence 
of cardiovascular disease and diabetes - i.e. disorders that might lie in the causal 
pathway between low birth weight and depression. A novel finding was that 
low birth weight increased the association between disease (CVD or DM) and 
depressive symptoms, which suggests that individuals with low birth weight are 
more vulnerable to depression associated with chronic disease such as DM or CVD.
6.3.2 Cognition
Subjects born with a low birth weight have on average lower cognitive performance 
throughout childhood and young adulthood (Richards, Hardy et al. 2001; Shenkin, 
Starr et al. 2004; Heinonen, Raikkonen et al. 2008; Räikkönen, Forsén et al. 2009). 
We are aware of only one previous study where the association between birth 
weight and cognitive performance in middle age or later life has been assessed 
(Martyn, Gale et al. 1996). That study found no association between the two. In our 
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study low birth weight was associated with a poor outcome in the DA and AL tasks 
independently of its association with DM, CHD or depressive symptoms. 
We hypothesised that being born with a low birth weight might also make 
diabetic subjects more vulnerable to the effects of diabetes on cognition. Indeed, 
we found evidence to suggest that this is the case. We saw an interaction between 
birth weight and known DM which indicated that subjects born with a low birth 
weight seem especially vulnerable to the prolonged effect of diabetes on working 
memory and learning. 
The mechanisms behind these interactions are not known but based on our 
findings we conclude that a lower birth weight seems to be a general indicator of 
vulnerability. 
6.4 Strengths and limitations
This thesis is based on five original publications. Studies I, II and V were clinical 
epidemiological studies with a cross sectional approach. The conclusions which 
may be drawn from the results in such a setting are limited. Most importantly 
statistical associations should not be interpreted as causal relationships and we can 
only speculate about the temporal and mechanistic aspects behind the detected 
relationships.
The question of selection bias is always relevant. The original cohort consisted 
of subjects born as singletons at the University Hospital in Helsinki during the years 
1934–1944. They attended the voluntary child welfare clinics, went to school in 
Helsinki, did not emigrate and were still alive in the years 2001–2006. Subjects who 
participated in the clinical study may differ in some aspects from the whole cohort 
and from the population at large. However, no statistically significant difference 
was found between participants in the clinical study and non-participants from the 
cohort regarding birth measures, socio-economic status and education. Whether 
they differed from the whole population is not known but since the results are based 
on internal comparisons within the sample they are likely to be representative. 
In study I we have to consider the possibility of a survivors’ bias. Those 
who attended the clinical examination in 2001-2004 are survivors and may have 
a different intellectual ability profile from those who died at an earlier age. It is 
possible that we could have found a correlation between intellectual ability and 
glucose tolerance if the non-survivors had been included in the analysis. 
Despite the mentioned limitations these studies have a large sample size 
and comprise a representative sample of the elderly population in Helsinki. The 
diagnosis of diabetes was based on a standardized oral glucose tolerance test which 
allowed classification of the subjects into different glucose tolerance categories. 
Cognitive ability and depressive symptoms were assessed with sensitive, validated 
tools. However, while the BDI is a well validated measure of depressive symptoms, 
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it cannot be used as a diagnostic tool. Therefore we do not have information on 
clinical diagnosis of depression in the study subjects. Likewise we did not have 
information on clinical dementia.
Studies III and IV were placebo controlled clinical trials. Both of them were 
limited by small sample size. In addition to this it is possible that the limited findings 
were partly due to the low level of depressive symptoms. However, considering the 
double-blind placebo controlled setting it would have been unethical to include 
severely depressed subjects since there is always the possibility of receiving placebo.
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7	 Summary	and	conclusions
This thesis aimed to explore risk factors, complications and co-morbidities of T2D 
from a life course perspective. The key findings related to the specific aims are 
listed below:
1.  Low intellectual ability per se is not an independent risk factor for T2D. 
However, regardless of intellectual ability or socio-economic status in 
childhood low educational attainment doubles the risk of future T2D among 
men. 
2.  T2D is associated with more depressive symptoms compared to subjects with 
normal glucose tolerance. This thesis adds to the literature by showing that 
this association is especially strong among subjects with CVD and those born 
with a low birth weight. 
3.  Treating depressed diabetic subjects with paroxetine has no long term effect 
on glucose regulation. 
4.  Subjects with known T2D have worse cognitive ability compared to both 
metabolically normal subjects and subjects with newly diagnosed T2D. 
5.  Low birth weight acts as a modifying risk factor with respect to diabetic 
complications. Both depression and cognitive impairment among diabetic 
subjects are increased if the subject is born with a low birth weight. 
Conclusions
Type 2 diabetes is a vast and complex public health problem which is accompanied 
by several complications and co-morbidities. Depression and cognitive decline 
are common, but often overlooked, complicators of T2D and further research is 
needed regarding their optimal treatment and prevention. Moreover, it should 
be recognised that low birth weight is an additional risk factor and modifier of 
diabetic complications.
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